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ABSTRACT
Three-dimensional (3D) cell cultures have been widely used in biological research since
two-dimensional (2D) cultures have many limitations including alteration of cell morphology,
metabolic pathways and gene expression. Therefore, the application of 2D cell cultures in
pharmaceutical companies for drug screening causes reproducibility issues in animal studies,
which strongly influences the efficiency of drug development. The aim of my studies is to develop
3D cell culture models to better mimic the extracellular matrix (ECM) in tumor microenvironment,
not only for deeper understanding of interaction between cells and ECM, but also for the
application in drug screening. Three different compositions of chitosan-alginate (CA) scaffolds
with different stiffness were produced to mimic prostate cancer (PCa) progression stages. The
results showed that PCa cells demonstrated stiffness independent growth and protein expression.
But surprisingly, it was found that CA scaffolds could identify PCa cell phenotypic characteristics.
Further, a novel 3D porous chitosan-chondroitin sulfate (C-CS) scaffold, with three CS
compositions, were developed to mimic the PCa progression, since the clinical research has
suggested that the CS is found in normal prostate tissue, greater in PCa, and further in metastatic
sites. The results showed that CS can promote PCa cell metastasis-related gene expression and
anti-cancer drug resistance. Although CA and C-CS scaffold provided more insights on PCa, 3D
cell culture is more complicated to use than 2D cultures, which limited its application in industry.
Therefore, a novel biomaterial format, named Frozen Films, were developed to combine the
advantages of 2D and 3D culture while reducing their drawbacks. Cell cultures tested on Frozen
Films demonstrated that cells had 3D culture performance, but with much easier operation process.
Overall, those studies demonstrated that CA scaffolds, C-CS scaffolds and Frozen Films could be
iii

promising in vitro platforms for cellular research, with potential applications for in vitro anticancer drug screening.

Keywords: prostate cancer, tumor microenvironment, mechanotransduction, tumor model,
mineralization, polyelectrolyte complex, cellular solids, natural polymers
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CHAPTER 1: INTRODUCTION
Prostate cancer (PCa) is one of the most commonly diagnosed cancers and is estimated to
be the second leading cause of death for men in the US in 2019 [1], with 1 out of 33 PCa patients
dying from it [2]. Primary PCa is curable, but most of the mortalities were from metastatic PCa.
Metastasis is the process that cancer cells spread out from primary site and form a new tumor in
other organs [3]. Bone metastasis occurs most frequently for PCa and could be explained by
Paget’s ‘seed and soil’ theory [4], where bone microenvironment acts as a fertile soil that attracts
PCa metastatic cells. Androgen-deprivation therapy (ADT) is one of the most commonly used
treatments for metastatic PCa, however, it may also cause the development of androgen-dependent
PCa into castration-resistant PCa [5, 6], an advanced form of PCa with few treatments [7].
The tumor microenvironment (TME) is a complex network that surrounds tumor, which
contains extracellular matrix (ECM) and various types of cells, like fibroblasts, endothelial cells,
and immune cells [8]. The ECM is a three-dimensional (3D) network formed by proteins,
polysaccharides, glycoproteins, and proteoglycans. ECM components not only perform as physical
supports but also influence the cell morphogenesis, proliferation, and migration [9]. ECM is a
dynamic system that is remodeled continuously with tight regulation by controlling the activities
of ECM enzymes, like matrix metalloproteinases (MMPs), heparanases, and urokinase. The
deregulation of ECM is commonly observed in cancer, including increasing of ECM stiffness,
changing in composition and overexpression of ECM enzymes [10]. The ECM stiffness increases
during cancer progression, which promotes the development of more aggressive and metastatic
phenotypes in several cancers [11-13]. Prostate tissue stiffness, measured with shear wave
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elastography, increases from 42 kPa for the normal prostate tissue to 88 kPa for the PCa tumor
[14].
Two-dimensional (2D) cell cultures are commonly used for biological studies, however,
cell growth on 2D surfaces have dramatic differences in cell response compared with in vivo. 2D
cultures alter cell morphologies, proliferation, gene expression, metabolic pathways, and ECM
production compared with in vivo [15-17]. These differences may cause novel cancer treatments
work efficiently in 2D culture but poorly in patients, leading to inefficient drug development.
Consequently, 3D cell cultures were developed to overcome the limitations of 2D culture and
better mimic in vivo TME and cell responses. In addition, 3D cultures enhanced the drug resistance
of cancer cells [18, 19], which suggests that 3D cultures could provide more predictive responses
than 2D cultures in drug development. Multicellular tumor spheroids [20] and engineered
biomaterial scaffolds [19] are the two types of 3D cultures. Multicellular tumor spheroids are
formed through several methods, such as hanging drop, low attachment plates, and bioreactor, and
rely on the self-aggregation of cells but lack of cell-matrix interaction. On the contrary, cells
cultured on biomaterial scaffolds have physical contact with the biomaterials. Therefore, the
biomaterial selection is essential, since the chemical and mechanical properties influence cell
responses.
Chitosan is derived from crustacean shells [21] and is a commonly used biomaterials due
to its biodegradability, biocompatibility, hydrophilicity, and low immunogenicity [22]. Chitosan
is cationic when dissolved in water, allowing formation of polyelectrolyte complexes (PECs) with
anionic polymers, like alginate and chondroitin sulfate (CS) through electrostatic interactions [23].
Alginate is a natural polysaccharide obtained from brown seaweed and is a commonly used
biomaterial due to its biocompatibility and ionotropic gelation with divalent cations [24]. Alginate
2

has been used as hydrogels, microspheres, sponges, and fibers for various applications, such as
wound healing [25], bone regeneration [26] and drug delivery [27]. CS is a sulfated
glycosaminoglycan (GAG) composed of N-acetylgalactosamine and glucuronic acid and is
commonly found as a side chain of proteoglycans. CS is expressed in normal prostate tissue and
overexpressed in primary PCa [28] and further upregulated in the peritumoral stroma of metastatic
PCa [29]. This suggested that CS is positively associated with PCa progression and could indicate
poor PCa prognosis [30].
Here, we present two completed projects and one nearly completed project. In the first
completed project, three CA scaffold compositions, 2 wt%, 4 wt%, and 6 wt%, were prepared
to assess the influence of CA scaffold stiffness on PCa response. The three CA scaffold
compositions approximated the stiffness of three stages of PCa malignant progression,
including normal prostate tissue, primary PCa tumor, and bone metastatic niche. Three PC
cell lines, PC-3, C4-2B and 22Rv1 were cultured on CA scaffolds for 15 d. The PC-3 cells
demonstrated cell cluster morphology while the C4-2B and 22Rv1 cells demonstrated
multicellular spheroid morphology. All three cell lines had stiffness-independent cell growth
and expressed phenotypic PCa biomarkers. C4-2B and 22Rv1 are osteoblastic cells and
mineralized in basal media, while osteolytic PC-3 did not, suggesting that CA scaffolds could
reveal PCa cell phenotypic differences. This project suggested that CA scaffolds could be used
to identify PCa phenotypic characteristics, with potential application for primary cancer in
vitro drug screening.
In the second completed project, novel 3D porous chitosan-CS (C-CS) scaffolds were
developed for PCa in vitro study. Three C-CS scaffold compositions, 4 w/v% chitosan with 0.1,
0.5, and 1.0 w/v% CS, were prepared and named 4-0.1, 4-0.5, and 4-1, respectively. PC-3 and
3

22Rv1 cells were cultured on C-CS scaffolds to evaluate the effect of CS concentrations on
PCa epithelial to mesenchymal transition (EMT). All C-CS scaffolds supported PC-3 and
22Rv1 cell growth and both cells had the highest cell number on 4-1 scaffolds throughout the
culture. The C-CS scaffolds promoted upregulated EMT marker expression of PCa cell lines,
where 22Rv1 had the highest EMT marker expression on 4-1 scaffolds. The expression of
some EMT markers was upregulated with increasing CS concentration. PC-3 and 22Rv1 cells
cultured on C-CS scaffolds had greater docetaxel drug resistance than 2D cultures, and 4-1
cultures had the greatest drug resistance. The results from this project suggested that C-CS
scaffolds are potential platforms for PCa in vitro studies and drug screening.
Although we got exciting results from these two projects, the operation of 3D cultures
was very challenging. The cell seeding process is more complicated and time-consuming than
2D culture. Cells in 3D spheroids within the scaffolds were hard to be focused all at once in
microscopy, since they are at different focal planes. Additionally, the downstream analysis of
3D culture, including cell harvesting, RNA extraction, PCR, RNA sequencing, and flow
cytometry are more difficult to perform than 2D culture. Therefore, in final project, we
developed a new biomaterial substrate which combines the benefits of 2D and 3D culture,
while avoiding their weaknesses. We named this new in vitro cell culture substrate Frozen
Films, which is a thin layer that contains micron-scale porosity and fibrous struts. Frozen
Films have been prepared from 2 w/v% chitosan and 1 w/v% chitosan with collagen with three
different thicknesses: 20 µm, 60 µm, and 200 µm. Control groups included the same materials
prepared as 3D porous scaffolds and 2D air-dried films, along with commercialized 3D cell
culture models, Matrigel and ultra-low attachment plates. We have collected the material
characterization data, including SEM images, pore size, thickness and stiffness. We have
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cultured mesenchymal stem cells, lung cancer cells and prostate cancer cells on Frozen Films.
We tested mesenchymal stem cells for differentiation, lung cancer cells for natural killer cell
test and prostate cancer cells for drug screening test. The data collected indicated that Frozen
Films are able to support cells growth like 3D cell culture, but much easier to be used than
3D porous scaffolds, Matrigel and ULA, which suggested that Frozen Films could be used
for industry application for drug screening and immunotherapy development in the future.
We have already applied for US and international patents and the manuscript is in
preparation and will be submitted soon.
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CHAPTER 2: STATE OF THE ART
2.1. Cancer
2.1.1 Background
A tumor is formed by abnormal and uncontrolled proliferation of cells in the human body.
Tumors are either malignant or benign, where the malignant tumor, referred to as cancer, grows
faster and spreads to distant organs, while the benign tumor grows slowly, cannot spread to other
organs and is unusually harmless. The earliest recorded description of cancer can be traced back
to 3000 BC, originated by Hippocrates, who is often referred as “Father of Medicine” [31].
Hippocrates thought the shape of tumor looked like crabs, so he used carcinoma, the Greek word
for crab, to name the tumor [31, 32]. Cancer is the second leading causes of death in the US [33].
It is estimated that around 606,800 Americans will die from cancer and additional 1.7 million new
cancer cases will be diagnosed in 2019 [33].
Cancer is classified into three main groups: carcinoma, sarcoma, and leukemia or
lymphoma, where carcinoma is formed by epithelial cells, sarcoma arises from connective tissues,
and leukemia or lymphoma are formed by hematopoietic cells [31, 34]. Cancer is often initialized
by genetic damage or mutation of cells, which could be caused by chemical carcinogens and
ultraviolet irradiation [35]. The p53 tumor suppressor gene initiates apoptosis when cell has
irreparable DNA damage, but the p53 gene is commonly mutated in human cancer [36]. Cell clones
is a group of cells that share a common ancestor and similar genotype, which form after
uncontrolled proliferation, which [37]. Cancer cells are heterogeneous and will have varied
properties, like motility, morphology, gene expression, and proliferation rate. Cells with higher
proliferation rate will form a larger cell clone and become dominant in the tumor. This process is
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similar to Darwin’s theory of evolution and provides insights into understanding cancer
progression and therapy [37, 38]. The normal cell experiences contact inhibition of proliferation
and locomotion during growth, where cells will cease motility and division in high confluency [39,
40]. However, cancer cells lack this property and the tumor size increases uncontrollably [41]. As
the tumor grows larger, the growth is suppressed by several extrinsic barriers, including hypoxia,
reactive oxygen species (ROS), basement membrane, tension force, inhibitory cytokines, and
immune surveillance [42]. Hypoxia occurs when there are too many cells that oxygen supply is
not sufficient for cell survival and leads to cell apoptosis. ROS generated by immune cells or
cancer cells during metabolism could cause DNA damage, which also causes apoptosis. Some
cancer cells may be unable to overcome or bypass those suppressive forces and eventually regress
or find a balance with these pressures [42]. On the other hand, cancer cells with higher
aggressiveness may overcome these pressures and play an important role in further metastasis [42].

2.1.2 Cancer Metastasis
Cancer metastasis is a process where cancer cells spread from the primary tumor site to
another part of body. Metastasis consists of five steps: invasion/dissociation, intravasation,
circulation, extravasation and colonization that are shown in Fig. 1 [43, 44]. The most famous
theory for metastasis is Stephen Paget’s seed and soil theory, which stated that cancer cells were
seeds that had an organ-preference pattern and were attracted by a certain nourishing
microenvironment in the target organ [45]. This theory has been recognized for over a century and
confirmed by many clinical data and experimental research [46].
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Figure 1 Cancer metastasis progression [47] Cancer cell migrates out of the primary tumor,
intravasates and circulates in the blood vessel. Circulating cells will attached to the endothelial
cells and extravasate out of blood vessels and invade into the new tissue. Finally, the metastatic
cancer cells form a new tumor in the distant tissue.
During invasion, cancer cells detach from the primary tumor, break through the ECM and
migrate into vessels. Therefore, only cancer cells with diminished cell-cell interaction, high
motility, and ability to disrupt ECM can invade. EMT is one of the most important steps in cancer
cell invasion. Epithelial cells are sedentary and tightly packed in a continuous sheet, while
mesenchymal cells have higher cellular motility [48] and plasticity [49, 50] that can migrate easily.
Therefore, EMT helps cells to gain the ability to detach from the tumor and migrate. Cancer cells
also overexpress MMPs, a group of enzymes that can degrade ECM proteins and help cells to
penetrate the basement membrane [51].
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Intravasation is the process where cancer cells enter the blood or lymph vessel and is a
common way for cancer cells to spread throughout the body [52]. However, blood vessels are often
located away from tumor, so the tumor angiogenesis becomes important for intravasation (Fig. 2).
As the tumor grows and reaches a critical size, cancer cells will have insufficient oxygen and
nutrient supply resulting in hypoxia, which could promote angiogenesis [53, 54]. Cells will turn
on the angiogenic switch by overexpressing angiogenic factors, like vascular endothelial growth
factor (VEGF), so the balance between angiogenic and anti-angiogenesis factors will be broken
and resulting in pro-angiogenic outcomes [18, 54]. The overexpression of angiogenic factors
activates and attract the migration and proliferation of endothelial cells towards tumor. This results
in the formation of capilaries that will connect tumors to vessels and promote intravasation of
cancer cells into the vasculature [55].

Figure 2 The sequential steps of tumor angiogenesis [52]. 1) cancer cells start to secrete
angiogenic growth factors (GF), 2) GFs activate the endothelial cells migrating and proliferating
toward the tumor. 3) endothelial cell tip (CT) gets closer to the tumor, 4) tumor connect to the
vasculature.
Cancer cells are called circulating tumor cells (CTCs) after they intravasate and circulate
in vessel until extravasation or death. Only a very small number of cells can survive during
circulation due to the severe microenvironment, including hemodynamic shear stress and cytotoxic
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immune cells [3, 56, 57]. Less than 0.01% of CTCs can successfully form metastatic foci [58].
Cancer cells will protect themselves by forming clusters with other cancer cells or host cells, like
platelets and macrophages to survive during circulation [59]. Platelets can cover cancer cells and
form a physical shield, which can protect the cancer cell from immune elimination and prevent the
exposure to hemodynamic shear stress [60-62].
Extravasation is the process where cancer cells move out of the vessel and into the tissue
of distant organ. This process can be separated into three steps: 1) docking, where cancer cells
attach or arrest to the endothelium, 2) locking, where cancer cells advance the cell contact with
endothelial cells, and 3) trans-endothelial migration, where cancer cells modify their cytoskeleton
to migrate through the endothelium [63]. The interaction between cancer cells and endothelial cells
depends on various receptors including selectins, integrins, and cadherins [64]. Selectin is a family
of cell adhesion molecules that is commonly expressed by endothelial cells. The major selectin
ligands are mucins, which is a group of heavily glycosylated proteins that overexpressed on lung,
breast, and colon cancer cells suggesting that selectin-mucin interaction could play an important
role in extravasation [65]. Cancer cells can also promote extravasation independently. Melanoma
cells can secrete osteonectin, a type of glycoprotein that binds to vascular cell adhesion protein 1
on endothelial cells to promote the endothelial actin remodeling and opening of endothelial
junctions to facilitate the extravasation.
After extravasation, the cancer cells infiltrate the distant tissue and are called disseminated
tumor cells (DTCs). Clinical observations suggested that tumor formation in a metastatic site was
an inefficient process, where most of the cells die due to severe foreign microenvironment and
only a minority of them survived to form tumor [47]. Immune surveillance in the foreign
microenvironment is the major defense against metastasis, where DTCs are particularly vulnerable
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to cytotoxic T cells and natural killer cells [66]. Therefore, DTCs must evade to the host-tissue
defenses and adapt to the supportive specialized niches in order to survive [47]. DTCs that survive
could enter dormancy, where the cells are in a state of proliferative quiescence, which could be
caused by the insufficient vascularization and constant immune defense. Dormant cells can achieve
long-term survival and evade therapies [67]. After DTCs break out of latency, they will initiate
overt growth, occupy the local tissue microenvironment, and eventually form a metastatic tumor.

2.1.3 Prostate Cancer
In 2019, PCa is estimated to be the second cause of death for men, and 174,650 new cases
will be diagnosed, which is the top among cancers in the US. The endogenous risk factors of PCa
include family history, race, and age: 1) men have a higher risk of PCa if their family members
had PCa, 2) black people have a higher incidence of PCa than white people, and 3) the risk of PCa
increases with age [68]. The exogenous risk factors of PCa include diet and environmental agents,
where the fat consumption and endocrine disrupting chemicals have a positive correlation with
PCa incidence and mortality [68].

2.1.3.1 Primary Prostate Cancer
Prostate is an exocrine gland that belongs to the male reproductive system. The histological
division of the prostate can separate to three zones, central zone, transitional zone, and peripheral
zone. Central zone surrounds the ejaculatory ducts. Transitional zone located centrally and
surrounds the urethra. Peripheral zone composes the main body of the prostate and contains the
majority of prostatic glandular tissue. Prostate cancer starts as prostatic intraepithelial neoplasia
(PIN), which is a condition that prostate epithelial cells have a neoplastic growth in benign
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prostatic acini or ducts [69]. PIN can be classified as low-grade PIN and high grade-PIN. Lowgrade PIN is not significant and normally will not be on the biopsy report, while high-grade PIN
is often recognized as the precursor of PCa [70]. More than 30% of high grade-PIN patients will
develop PCa within a year. Most of PCa originate from the peripheral zone and is relatively slowgrowing, which may take years to grow large enough to be detected. The prostate epithelial cells
grow within the basement membrane in normal prostate. However, cancer cells will have
uncontrolled proliferation and migrate out of the basement membrane and spread throughout the
prostate.

2.1.3.2 Metastatic Prostate Cancer
Primary PCa is curable, but most of the fatal cases are from metastatic PCa, and
approximately 90% of the metastasis is to bone (Fig. 3) [71]. Prostate is a highly vascularized
organ and has blood vessels drain to the bone, which may be one of the routes for PCa metastasis
to bone [72]. The mechanism for bone metastasis is based on the seed and soil theory, where bone
is a nourishing soil that can attract PCa cell extravasation, since bone is continuously being
remodeled and releasing potential chemo-attractants including collagen [73], low glycosylated
osteonectin [74], purified fibronectin [75], and epidermal growth factor [76]. Endothelial cell
adhesion can also mediate the metastasis of PCa. Studies have shown that PCa CTCs prefer to
adhere to human bone marrow endothelial cells rather than human umbilical vein endothelial cells,
human dermal microvascular endothelial cells, or lung endothelial cells, which suggested that bone
microenvironment may be an attractive soil for PCa CTCs [77-80].
Metastatic PCa cells will evolve to have osteomimetic properties, where PCa cells alter the
phenotypes to more osteoblast-like [81, 82] to better survive, adhere and grow in highly restricted
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and protective bone microenvironment [83]. Osteoblast is a type of bone cells that responsible for
synthesis and mineralization of bones, while osteoclast is the cell that breaks down bones. The
osteomimetic PCa cells can secrete and synthesis non-collagenous bone matrix proteins, like
osteopontin, bone sialoprotein, and osteocalcin [84-86]. Osteolytic lesions may also be found
together with osteoblastic lesions in PCa metastasis, but the osteoblastic lesion is still the
predominant [87]. Although PCa cells can promote the bone formation, the bone induced by PCa
is woven bone, which is loosely packed and randomly oriented with low strength [88, 89]. PCa
cells can also endogenously secrete or induce the expression of interleukin 6 (IL-6), a proinflammatory cytokine that is normally expressed by osteoblasts to stimulate osteolysis [90]. In
return, the bone resorption process releases calcified bone matrix that will further promote the
tumor growth [91].

Figure 3 PCa metastatic process and crosstalk to bone microenvironment [92]. 1) PCa metastatic
cells circulate in blood vessels, 2) the PCa CTCs attach to the bone marrow endothelial cells, 3)
CTCs extravasate into the skeletal extracellular tissue, 4) PCa metastatic cells stimulate
osteoclasts to break down bones, 5) induced bone resorption releases growth factors that promote
PCa metastatic cell proliferation, 6) PCa cells release factors that promote osteoblasts to synthesis
bones and inhibit osteoblast apoptosis.
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2.1.3.3 Prostate Cancer Treatment
The commonly used PCa treatments include radiation therapy, chemotherapy, and ADT.
Androgen, or testosterone, is a steroid hormone that is required for primary PCa growth [93].
Androgen also has a negative immunomodulatory effect [94] and can increase the expression of
DNA repair genes [95]. ADT (surgical or chemical castration) blocks androgen supply and restricts
the PCa progression, which makes it the first line PCa treatment [93]. Further investigation also
shows that ADT can cause inflammation by inducing T cell infiltration [96], which could cause
more PCa cell death [94]. The combination of radiation therapy and ADT has better results than
each individual treatment, since radiation therapy treats the cancer by damaging its DNA [95]. The
PCa recurrence after treatments often is castration-resistant prostate cancer (CRPC) [97], which is
an advanced form of PCa that can keep growing despite ADT [98].

2.2. Tumor Microenvironment
TME includes cancer cells and their environment, which includes ECM, growth factors,
immune cells, cancer-associated fibroblasts (CAF), and blood vessels (Fig. 4). TME has been
shown to not only support tumor growth but also promote the tumor development and metastasis
[99].
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Figure 4 PCa tumor microenvironment [100]. The PCa TME is a highly heterogeneous system
that contains extracellular matrix and multiple cell types, like cancer cells, neuroendocrine cells,
normal fibroblasts, cancer-associated fibroblasts, and immune cells.

2.2.1 Extracellular Matrix
ECM is a dynamic network that surrounds cells, which is formed by proteins, glycoproteins,
proteoglycans, and polysaccharides with different biomechanical and biochemical properties (Fig.
5). ECM not only supports cell growth but also regulates the cell proliferation, differentiation,
migration, and morphogenesis through cell receptors [9]. There are two main types of ECM: 1)
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pericellular matrices, which have direct contact with cells, like the basement membrane that cells
anchored with hemidesmosomes, 2) interstitial matrices, which surround the pericellular matrices
(Fig 5) [101]. The basement membrane contains laminins, perlecan, and collagen type XV [102]
and separates the epithelial cells from connective tissue [103]. The interstitial matrices contain
hyaluronan, elastin, fibronectin, and collagen fibrils and could perform as a compression buffer
against the stress.

Figure 5 Overview of extracellular matrices [101]. ECMs are classified into interstitial matrices
and pericellular matrices. Basement membrane belongs to pericellular matrix, which is between
epithelial cells and connective tissue. The main components of basement membrane are collagen
IV, nidogen, laminin, and perlecan. Interstitial matrices are composed of collagen fibrils, HA, and
elastin. Epithelial cells interact and bind to ECM components through cell surface receptors, like
integrins.
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Collagen is the most abundant protein in mammals and is found in both interstitial and
pericellular matrices [104]. There are a total of 28 types of collagen, where type I collagen is the
most common one found in tissues, like tendon, dermis, and bone [105]. Fibrillar type I collagen
was shown to enhance the ovarian cancer invasiveness through mediating PTEN/PI3K/AKT
signaling pathway [106]. Type IV collagen promotes EMT for mammary epithelial cells by
downregulating E-cadherin expression and upregulating N-cadherin and MMP-2 expression [107].
Type XXIII collagen was upregulated for metastatic PCa cells in experiment [108] and has been
used as a tissue biomarker for PCa recurrence [109]. Type XXIII collagen expression by PCa cells
also facilitated endothelium adhesion, which enhances the extravasation during metastasis [110].
All these findings suggest that the interaction between collagen and cancer cells plays an important
role in cancer progression. Hyaluronic acid (HA), also known as hyaluronan, is a linear GAG
comprised of D-glucuronic acid and N-acetyl-D-glucosamine. During tumor progression, HA can
promote proliferation, motility, and invasion through binding with CD44 [111]. In addition, the
HA degradation product with 3–10 disaccharide unit size could induce an angiogenic response
[112] and the cooperation with VEGF could promote angiogenesis through the induction of
endothelial cell migration and proliferation [113].
Versican is a large proteoglycan with chondroitin sulfate on side chain. Versican influences
cell adhesion, proliferation, and migration [114]. Versican promotes glioblastoma (GBM) cell
adhesion by activating the focal adhesion kinase through β1 integrin [115]. Versican is primarily
synthesized by fibroblasts and cancer cells in the TME, where versican could bind with cell
receptors, like epidermal growth factor receptor (EGFR), to enhance the cancer invasion and drug
resistance [116]. PCa cells induce the secretion of versican from stromal cells through
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transforming growth factor-β (TGF-β) [117] and the expression of versican was found to be
positively correlated with PCa progression [28].
There are other ECM components that could promote cancer progression, like laminin and
fibronectin. Laminin is a heterotrimeric cross-shaped glycoprotein that contains one α-chain, one
β-chain, and one γ-chain [118]. There are total of fifteen laminin isoforms that perform various
functions and play a critical role in early organogenesis and embryonic development [119, 120].
In TME, laminin-332 was found to promote breast cancer cell invasion and survival through
binding with cell receptors to activate the PI-3K and RAC1 [121]. Fibronectin is a glycoprotein
that is commonly found in ECM and plays a key role in cell adhesion [122]. Fibronectin is crucial
for the embryonic development and is often produced during the tissue formation, remodeling, and
repair [123]. Fibronectin plays an important role in angiogenesis by activating endothelial cells
and the overexpression of fibronectin near the tumor vasculature suggests that fibronectin could
promote tumor angiogenesis [124, 125].
ECM is a dynamic system that tightly regulated through the controlling of ECM enzymes,
like MMPs, heparanases, and urokinase. However, those ECM enzymes will be overexpressed in
cancer, which lead to the deregulation of ECM dynamic and the ECM deregulation has been
recognized as a hallmark of cancer in clinical studies [10]. The abnormal changes in ECM quantity,
structure, and compositions promote tumor development and progression [10]. In breast cancer,
the structure of type I collagen was fundamentally changed, where it is highly linearized or
projecting perpendicularly compared with relaxed nonoriented fibrils in normal tissue [126].
Tumors normally have higher stiffness than normal tissue. PCa stiffness was measured with shear
wave elastography, where PCa had a stiffness of 89 kPa, which is higher than prostate tissue with
stiffness of 42 kPa [14]. One of the mechanisms for increasing stiffness is the overexpression of
18

lysyl oxidase (LOX), which could crosslink collagen with various ECM components. This was
suggested by LOX overexpression in many cancers like head and neck cancer [127] and breast
cancer [128]. Furthermore, the crosslinking of collagen by LOX could induce invasion through
enhancing the focal adhesions (FAs) and inducing PI3 kinase activities [11], which suggest that
increasing ECM can promote the tumor progression. ECM also plays an important role in tumor
angiogenesis. Collagen and laminin are the main components in basement membrane of new
formed blood vessel, however, the tumor vasculature formed is porous and cells can easily leak
out, which could promote metastasis and facilitate tumor progression [129]. ECM could also
influence the EMT of cancer cells. Periostin upregulated Snail expression and downregulated ECadherin expression in PCa, which enhanced the invasiveness [130]. Furthermore, ECM acts as a
physical barrier to protect cancer cells from drug treatment and slows down the migration of
immune cells [131], which suppresses the efficiency of cancer therapies [132].

2.2.2 Growth Factors and Cytokines
Growth factors are expressed by both cancer cells and stromal cells to influence the tumor
development. TGF-β is one of the most important growth factors in TME. It has three isoforms
(1–3) and is associated with cancer proliferation, motility, and apoptosis [133]. TGF-β can perform
as an anti-inflammatory factor to suppress immune system [134] and remodel the ECM by
regulating the production of enzymes, like MMPs and LOX [135]. Prostate cancer cells secrete
TGF-β after metastasizing to bone to induce the deposition of ECM components, like collagen,
osteonectin, elastin, and fibronectin, to improve the survival of metastatic cells [136]. TGF-β
expression was upregulated for both epithelial cells and stromal cells in PCa, but not in PIN or
benign prostate hyperplasia [137].
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Other growth factors that are active in the TME include platelet-derived growth factor
(PDGF), VEGF, fibroblast growth factors (FGFs), insulin-like growth factor-1 (IGF-1) and EGF.
PDGF is a group of proteins that mainly expressed by fibroblasts, endothelial cells, and neurons
[133]. PDGF signaling induces the expression of other growth factors, like TGF-β or IGF-1 [138],
and is correlated with angiogenesis, cell invasion, and EMT [139]. VEGF is a key factor in
angiogenesis and could regulate the proliferation and motility of endothelial cells [136]. VEGF is
only expressed by stromal cells in benign prostatic hyperplasia, but it can be expressed by both
epithelial cells and stromal cells in PCa [140]. Overexpression of VEGF promotes PCa invasion
and the serum VEGF level could be used as a prognostic marker for PCa bone metastasis patients
[140]. FGF is one of the most common mitogens that can start cell division. Overexpression of
FGF enhances cancer proliferation, motility, invasion, metastasis and resistance to apoptosis and
chemotherapies. FGF 1, FGF 2, FGF 6, and FGF 8 were overexpressed in PCa, where FGF 1 is
most closely correlated with PCa progression [141].
IGF-1 is mainly expressed by fibroblasts and promotes the tumor growth and invasion
[142]. It also has interactions with androgen receptor (AR) in PCa, where the IGF-1 could stimulate
the AR activity of PCa cells and the inhibition of IGF-1 receptor on PCa cells could cause the AR
retention and influence the expression of androgen-regulated genes [143]. EGF is protein that
could promote cancer cell motility and invasion through the EGFR/erbB1 and erbB2/Her-2
pathway [133]. EGF is commonly found in bone and is one of the chemoattractants for the PCa
bone metastasis [138]. The EGFR is a transmembrane protein tyrosine kinase and its
overexpression is correlated with the appearance of CRPC and metastatic properties for PCa [144].
The expression of EGFR in tumor is also correlated with the PCa metastasis, where PCa CTCs
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were found to express EGFR [145]. The metastatic PCa have higher immunoreactivity of EGFR
than patients without metastasis [146].
Cytokines are a category of small proteins and sometimes the name is used interchangeably
with growth factors. Historically, cytokines were more associated with immune system and were
the main modulators of immune cells, Interleukin 6 (IL-6) performs as a pro-inflammatory
cytokine that is commonly expressed by stromal cells and is associated with cancer proliferation,
survival, angiogenesis, and metabolism. Furthermore, IL-6 induces the counter signaling pathways
to repair the therapy-induced DNA damage of cancer cells [147]. CXCL12, also known as stromal
cell-derived factor 1, is a cytokine that is correlated with PCa bone metastasis through binding
with C-X-C chemokine receptor type 4 [148]. CXCL12 can also stimulate cancer growth and
survival, and facilitates angiogenesis through the attraction of endothelial cells [149]. These
findings suggest that growth factors and cytokines secreted by cancer cells or stromal cells promote
tumor progression.

2.2.3 Immune Cells
Immune cells, like T-cells and macrophages, can suppress tumor growth by detecting and
eliminating cancer cells. Macrophage is a type of white blood cell, which engulfs and digests
foreign substances and cellular debris. Macrophages can be classified to M1 macrophages and M2
macrophages based on different activation signals, where M1 performs as a killer that can
eliminate infectious organisms and virus-infected cells, while M2 performs as a healer that can
repair wound tissues [150]. Type I interferon is a subgroup of interferon proteins that could
stimulate immune cells to elicit an anti-viral response. Type I interferons are induced during the
early tumor development and activate M1 macrophages to eliminate cancer cells by nitric oxide
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and tumor necrosis factor [151, 152]. On the other hand, immune defenses can select more
aggressive cancer cells since the cells that can survive in an immunocompetent host will dominant
further tumor growth [153]. Cancer cells escape the immune defenses by losing expression of
specific antigens that are recognized by immune cells. PCa cells will downregulate the cancertestis antigen to achieve lower immunogenicity and escape from immune surveillance [154]. The
cancer cells also are more resistant to immune cytotoxicity by expressing anti-apoptotic factors
such as BCL-2 [153]. Immune cells can also promote tumor growth. M2 macrophage, also known
as tumor-associated macrophages, is considered as the “pro-tumor” phenotype [155], which can
promote cancer angiogenesis by secreting pro-angiogenic factors and deregulate the ECM
remodeling by the expression of MMPs and plasmin [156]. M2 macrophages were also shown to
promote cancer proliferation, survival, and metastasis [157]. M2 macrophages were shown to be
positively correlated with PCa poorer prognosis [158].

2.2.4 Cancer-Associated Fibroblasts
CAFs are one of the most crucial components in TME, since the interaction between CAFs
and cancer cells has shown to promote tumor progression. The origin of CAFs has several sources:
1) the normal fibroblasts near the tumor [159], 2) the endothelial cells go through endothelialmesenchymal transition with upregulation of fibroblast-specific protein-1 and downregulation of
CD31/PECAM [160], and 3) circulating bone marrow stem cells [161, 162]. CAFs promote the
tumor progression through expression of growth factors. CAFs derived from metastatic colon
cancer patients expressed more growth-promoting factors in conditioned medium compared with
normal skin fibroblasts [163]. The proliferation of CAFs was correlated with the tumor
development, where the number of CAFs increased from PIN to the late stage of PCa [164]. CAFs
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also produce matrix-degrading proteases and their activators, like urokinase-type plasminogen
activator to promote the invasion of cancer cells [165]. CAFs promote cancer metastasis by
secreting VEGF to facilitate the tumor angiogenesis [8]. Exosomes are extracellular vesicles
produced by cells, which are enriched of lipids, nucleic acids, micro-RNA and growth factors for
mediating ECM remodeling or transmitting signals to other cells. The exosomes from CAFs have
shown to contain miRNAs, like miR-21 and miR-409 that can influence the cancer cell invasion,
proliferation and chemoresistance [166]. CAFs have become a new therapeutic target in cancer
treatment due to the promotion on tumor development. The target is not only to eliminate CAFs,
but also to inhibit CAF signals that promote tumor progression, invasion, and metastasis [167].

2.3. Cell culture
2.3.1 Two-Dimensional Cell Culture
In the past decades, 2D cell culture is the most commonly used system in cancer research
and other biological studies. The main benefits for 2D cell culture include: 1) easy to grow and
maintain, 2) easy downstream analysis, like RNA/DNA extraction, 3) the operation protocol is
highly standardized, simple, and reproducible [168]. However, cells in vivo are in a 3D
microenvironment with a more complex network, where they are surrounded by stromal cells, and
ECM. The disruption of cell-cell and cell-ECM interaction in 2D cultures changes cell
differentiation, proliferation, viability metabolic pathways and gene expression compared with in
vivo [17, 169, 170]. In addition, cells grown in 2D cultures have a significant morphology change
compared to in vivo, which affect structure organization in the cells and cell signaling [171]. Cells
in 2D culture also have unlimited access to oxygen and nutrition in contrast to in vivo [172].
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Furthermore, 2D cultures alter the ECM production and leads to different drug responses compare
with in vivo, since the cells in vivo are overexposed to drugs without ECM as a physical barrier
[173].

2.3.2 Three-Dimensional Cell Culture
3D cell culture was developed to better mimic the normal tissue and tumor
microenvironments due to the limitations of 2D cultures. The main benefit of 3D cell culture is
that it can be engineered to simulate specific tissue microenvironments by mimicking the tissue
stiffness and ECM components [174]. Cell spheroid formation is often found in 3D culture, where
it simulates the in vivo oxygen and nutrient gradients, cell-cell interaction [175, 176]. The in vitro
cell spheroids with around 500µm diameter [177] could mimic the structure of in vivo tumor,
where the peripheral layer is exposed to the media and proliferates, the intermediate layer contains
quiescent cells and inner layer is necrotic core. 3D cell culture can be classified as two groups:
anchorage independent, anchorage dependent [178].
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Figure 6 Classifications of 3D cultures [178]. Compared with 2D cultures, 3D cultures have
complex structures that enhance cell-cell and cell-matrix interaction. Cells can form spheroids or
be encapsulated in 3D culture matrix.
2.3.2.1 Anchorage Independent 3D Culture
Anchorage independent 3D culture relies on the self-aggregation of cells to form spheroids
in methods like hanging drop, low attachment plates, bioreactor, and magnetic levitation. Hanging
drop is where a drop of cell solution suspended under the Petri dish lid or a specialized plate by
surface tension. Cells in the droplet will move to the bottom of the droplet due to gravity and
spontaneously form cell spheroids [179]. Phosphate buffered saline (PBS) or deionized water is
added in the dish or well to avoid the dehydration of cell solution droplets. The droplet size needs
to be carefully controlled: it should be large enough for cells to aggregate but small enough to
avoid dislodging during operation [178]. The advantages of hanging drop culture are high output
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of cell spheroid numbers and low reagent consumption, while the disadvantages are long culturing
time and transferring of cell spheroids for further analysis [180]. Hanging drop cultures have been
used in many biological studies, like the toxicity testing in hepatocytes [181] and co-culture of
induced pluripotent stem cells (iPSCs) with endothelial cells and fibroblasts [182]. Hanging drop
cultures have been used in cancer research, where ovarian cancer cells [183] and liver cancer cells
[184] demonstrated higher anti-cancer drug resistance compared with 2D.
Low attachment plates are culture plates coated with non-adherent polymers, like
polystyrene [185], and have round or v-shaped bottoms. These features prevent the cell attachment
and force the cell aggregation and spheroid formation. The downstream analysis of low attachment
plate culture can be done in the same plate without transferring, which makes it more user-friendly
than hanging drop culture. Other benefits for low attachment plate are it is inexpensive, high output
of spheroid number, easy for imaging and biochemical assay [180]. The disadvantages include
inconsistent cell spheroid sizes and cell attachment to the bottom of the plate [180]. The low
attachment plates are commonly used in cancer research. Head and neck cancer cells were grown
on low attachment plates to form spheroids for drug discovery assays [186]. In addition, pancreatic
cancer cells were grown in low attachment plates for cancer stem cell studies [187], and non-small
cell lung cancer cells were cultured for ionizing radiation treatment [188]. Bioreactors are systems
that continuously stir cells in liquid containers and force cells to form spheroids by random
collision. The advantage of bioreactors is that the system can be computer-controlled to regulate
the culture conditions, like oxygen concentration, temperature, pH and shear stress. Magnetic
levitation culture uses an external magnetic field to force cells preloaded with magnetic
nanoparticles to form a spheroid [189]. The advantage of magnetic levitation is that the
downstream analysis can be done in the same plate, while the disadvantages include that the
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magnetic beads are expensive and could be toxic to cells. Magnetic levitation has been used in
cancer research. Breast and colorectal cancer cells cultured with magnetic levitation recapitulated
some in vivo cell traits by highly expressing EGFR and N-cadherin [190]. Human GBM cells
cultured in a magnetic levitation system closely mimicked the protein expression of human tumor
xenografts [189].

2.3.2.2 Anchorage Dependent 3D Culture
Anchorage dependent 3D culture is designed to provide a physical support for cell growth
using natural or synthetic biomaterials to mimic the in vivo ECM. Cells have physical contact with
matrix in anchorage dependent 3D culture and the chemical and mechanical properties of the
biomaterial could influence the cell response. Therefore, the selection of material and
compositions for anchorage dependent 3D culture are crucial. Anchorage dependent 3D culture
includes: 1) hydrogel, where cells are encapsulated in the material, and 2) porous scaffolds, where
cells are on the surface of the matrix.
A hydrogel is a network of cross-linked polymer chains with over 95% of water in volume
[191]. Hydrogels used in 3D cell culture include collagen gel, Matrigel, polyethylene glycol (PEG),
and polylactic acid. Collagen is the most abundant ECM component in humans, making it a
commonly used hydrogels in 3D culture [176]. Collagen gel controled cell growth and
differentiation in bone cells [192] and cardiomyoblasts [193]. Collagen gel also has been used for
anti-cancer drug response testing, where breast, prostate, and lung cancers showed higher drug
resistance compared with 2D culture [194]. Matrigel is derived from Engelbreth-Holm-Swarm
mouse sarcomas, which primarily contains laminin, type IV collagen and several growth factors
like, EGF and PDGF [195]. The minimally processed content in Matrigel makes it a good
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simulation of the in vivo microenvironment. Matrigel has been used for breast [196] and prostate
[197] cancer in vitro studies, and was demonstrated to be a feasible in vitro approach for drug
testing of primary tumor slices from colorectal and lung cancer patients [198]. The disadvantages
of Matrigel are inherent heterogeneity and batch to batch variation since they are derived from
natural sources, which could make the experimental results non-reproducible. Compared with
natural hydrogels, synthetic hydrogels are cheaper and have better defined properties and contents.
PEG hydrogel is one of the most commonly used synthetic hydrogels, which has been used in
cancer research. Epithelial ovarian cancer cell line V-MZ-6 and SKOV-3 were cultured on PEG
hydrogel and demonstrated spheroid formation and drug resistance [199].
Porous scaffolds were developed for tissue engineering for in vitro cell growth and medical
implants. The most important factors in porous scaffolds are pore size, porosity, mechanical
properties, and compositions. Pore size and percent porosity influence cell viability and
proliferation for porous scaffolds, with pore sizes between 200 μm to 250 μm and greater than 85%
porosity promoting cell proliferation in vivo [200]. The mechanical properties and compositions
of porous scaffolds also influence the cell morphology, signaling pathways, and gene expression
[170, 201]. Numerous types and compositions of porous scaffolds have been developed by using
either natural polymers or synthetic polymers. They were not only used in tissue engineering but
also in cancer research to mimic tumor microenvironment. Synthetic poly(lactide-co-glycolide)
(PLG) scaffolds have been used for OSCC-3 cell culture, which promotes the cancer angiogenesis
and chemotherapy resistance [202]. Human glioma cells also have been cultured on PLG-based
scaffolds and the cells demonstrated greater drug resistance and upregulated anti-apoptotic protein
expression [203]. However, the synthetic polymer scaffolds have many limitations, including a
relatively slow degradation rate, lack of active site for cell adhesion and the use of organic solvent
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during the process could be toxic to cells [204]. Therefore, natural polymers, like collagen,
chitosan, and bacterial cellulose (BC), are preferable to make porous scaffolds. Breast cancer cells
cultured on collagen scaffolds demonstrated higher EMT marker expression and enrichment of
cancer stem cell properties, which suggested that collagen scaffolds could promote breast cancer
metastasis [205]. BC is a natural nanofibrous polymer produced by bacterium Acetobacter xylinum.
BC scaffolds cultured with breast cancer cells promoted cell proliferation and adhesion, which
suggested that BC scaffolds could be a potential platform for in vitro studies of breast cancer [206].

2.4 Chitosan-Based Porous Scaffolds
Chitosan-based scaffold is a commonly used natural material scaffolds for biological
studies. Chitosan is a polysaccharide that deacetylated from chitin and is commonly derived from
shrimp shells or other crustaceans. Chitosan is a commonly used biomaterial due to its
biodegradability, biocompatibility, high filmogenicity, hydrophilicity, low immunogenicity, and
unique cationic behavior. Polyelectrolyte complexes are association complexes formed by the
electrostatic interaction between oppositely charged polyions, which combine the benefits of each
polymer, while avoid their respective limitations. Most polymers are anionic, so chitosan could
form PEC with various natural polymers to mimic the compositions of in vivo ECM [22].
Chitosan-based PEC scaffolds have been widely used in biological studies by mixing chitosan with
alginate [207], collagen [208], HA [209], polycaprolactone (PCL) [210], gelatin [211] and silk
fibroin [212].
Alginate is derived from brown seaweed and is an anionic polymer that can form PEC with
chitosan. Alginate is often used as a hydrogel due to its biocompatibility and ionotropic gelation
with divalent cations [24]. However, alginate has no cell adhesion sites, so it is often conjugated
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with arginyl-glycyl-aspartic acid (RGD) peptides, the most common peptide motif for cell
adhesion, to promote cell-matrix interaction [213, 214]. Chitosan-alginate (CA) scaffold is one of
the most widely investigated chitosan-based scaffolds, which was initially developed for bone
tissue engineering, where CA was demonstrated to support osteoblast cell growth and promoted
the deposition of minerals [207]. CA scaffolds were further used in cancer studies. Kievit et al
used CA scaffolds to mimic GBM TME, where human U-87 MG and U-118 MG cells were
cultured on CA scaffolds and demonstrated significantly higher malignancy [215] and expressed
upregulated cancer stem cell markers [216]. In addition, hepatocellular carcinoma (HCC) cells
cultured on CA scaffolds had upregulated malignancy marker expression and implantation of the
CA scaffold cultures in mice promoted tumor growth [217]. Furthermore, CA scaffolds were used
as a model for in vitro nanoparticle-targeted gene delivery for PCa cells and were a better platform
than 2D cultures [218].
Chitosan-collagen scaffolds have been used to culture breast cancer cell line 4T1, where
cells demonstrated higher survival rate to the X-ray irradiation and enhanced chemotherapy
resistance compared with 2D cultures [219]. Chitosan-hyaluronic acid [209] and chitosan-PCL
[210] scaffolds were cultured with GBM cells and upregulated the invasion-related genes. Gelatin
is a protein that produced by partially hydrolysis of collagen, which is commonly found in human
skin, cartilage and connective tissues. Gelatin is commonly used biomaterial due to its
nonimmunogenic property and RGD-like sequence, which can promote the cell adhesion and
migration. Chitosan can form a PEC with gelatin to produce chitosan-gelatin porous scaffolds and
used in tissue engineering and cancer research. Chitosan-gelatin scaffold cultured with
keratinocytes and fibroblasts was demonstrated to successfully construct a flexible, biocompatible,
and biodegradable artificial skin, which suggested that chitosan-gelatin scaffold is suitable for skin
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regeneration [220]. Chitosan-gelatin scaffolds were cultured with cervical cancer cells, breast
cancer cells and osteosarcoma cells, where cells showed similar gene-expression profiles as the
cells grown in vivo and the drug resistance was also enhanced compared with 2D cultures [211].
Silk fibroin is a protein derived from silk produced by moth genera including Bombyx mori,
Cricula, and Samia. Silk fibroin is an attractive natural biomaterial due to its permeability to
oxygen and water, low thrombogenicity and inflammatory response, and good cell adhesion [221].
Pure silk fibroin scaffold is brittle and unstable, but it can be enhanced by mixing with chitosan.
Chitosan-silk fibroin scaffold has been used to mimic TME, where human hepatoma cells cultured
on chitosan-silk fibroin scaffold demonstrated higher cell proliferation rate [212].
Based on the studies mentioned above, chitosan-based scaffolds better mimic the in vivo
TME than 2D culture and promote cancer cell invasiveness, metastasis, and drug resistance. The
chitosan-based scaffolds could also be used in drug development by providing better and more
accurate responses. Although many different types of chitosan-based scaffolds have been
developed, more progress is still needed. TME contains cancer cells and different types of stromal
cells, so a porous scaffold that can be used for multicellular co-culture is needed to accurately
simulate the heterogeneous in vivo TME. The long range goal is to develop a 3D porous scaffold
that can closely mimic the TME and promote the growth of patient-derived cells to provide
significant insights into the tumor biology and drug screening.

2.5 Freeze-Casting
There are many different ways to produce porous scaffolds, like rapid prototyping [222],
gas foaming [223], and salt leaching [224]. However, those methods are often used to produce
synthetic polymer scaffolds due to the high temperature condition and the use of organic solvents.,
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Freeze-casting, also known as ice templating, is a versatile technique that produces porous polymer
and ceramic structures. The freeze-casting process (Fig. 7) includes: 1) prepare material solution,
2) cast the solution in a mold, 3) freeze the solution to form pores, and 4) freeze-dry the solution.
In this process, the water-based suspension is frozen and the ice crystals nucleate and grow,
pushing aside the solid phase [225, 226]. The freeze-drying process happens under low
temperature and low pressure conditions, where the solvent is removed by sublimation, leaving
the pores in the material, while maintaining the original shape. Therefore, the final porous
architecture is determined by the created solid ice structure which mainly affected by ice nucleation
and growth [225].

Figure 7. Schematic diagram for porous scaffold production using freeze casting.
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Except for the material, functional additives, like enzymes and antibiotics, can also be
added in the solvent at the beginning of the process since there is no high temperature process in
the following steps [227]. Processing additives, like beads and freezing additives, can also be
added in the solution to direct the pore size and freezing rate [227]. The porous properties including
pore size, orientation, shape, and porosity, are defined by the growth of solvent crystal, which
could be manipulated during the freeze-casting process [228]. The pore orientation can be
controlled by the direction of thermal diffusion [229]. The pore size can be manipulated by the
solution viscosity, freezing rate, and freezing time. High solution viscosity constrains the
molecular motion during freezing and mechanically limit solvent crystal growth, leading to smaller
crystal size and smaller pore size [230, 231]. Ostwald ripening could happen during freezing,
where large crystals will grow larger by annexing smaller crystals [230]. Freeze-casting has many
other benefits, including low cost and simple operation process, which made it a commonly used
method for production of porous scaffolds.
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CHAPTER 3: 3D POROUS CHITOSAN-ALGINATE SCAFFOLDS
STIFFNESS PROMOTES DIFFERENTIATIAL RESPONSES IN
PROSTATE CANCER CELL LINE
Xu, K., Ganapathy K., Andl T., Wang Z., Copland J.A., Chakrabarti R., Florczyk, S.J. Biomaterials 2019;
217: 119311

3.1 Introduction
PCa is a leading cause of death for men; 1 out of 6 men over age 50 in the United States
will be diagnosed with PCa and 1 out 33 will die from it [2]. Primary PCa is curable, while the
fatal cases are typically recurrent and metastatic PCa. Metastasis is the process of cancer spreading
from the primary tumor to other organs [3]. Approximately 90% of PCa metastasis is to bone,
which makes bone metastasis the predominant source of PCa mortality [71]. Based on Paget’s
‘seed and soil’ theory of cancer metastasis [4], the bone microenvironment provides a fertile soil
to PCa cells growth compared with other organs. PCa cells may be attracted to bone by stromal
factors [232]. PCa cells preferentially metastasize to cancellous bone, where the osteoblastic
(mineralizing) PCa cells and occasionally osteolytic PCa cells colonize in the vascular beds [233].
2D cell cultures are commonly used for in vitro studies evaluating cancer therapies.
However, there are considerable differences in cell response between 2D cultures and in vivo
growth. 2D culture alters cell morphologies, metabolic pathways, gene expression, and
proliferation rate compared to in vivo conditions and also reduces extracellular matrix protein
production [17, 234, 235]. These differences between 2D culture and in vivo growth lead to
differential responses from cancer treatments in 2D cultures and patients, potentially resulting in
drugs that appeared to be efficacious during preclinical screening to perform poorly. Consequently,
researchers have developed 3D cultures of cancer cells in several formats that demonstrate
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responses that better match those observed in vivo. The use of 3D cultures and particularly 3D
biomaterial scaffolds for culture of cancer cells results in cultures that are more drug resistant and
release more growth factors and extracellular matrix proteins than 2D cultures [202, 209, 236].
Therefore, further development and characterization of 3D biomaterial scaffold cultured cancer
cells under multiple conditions that recapitulate the in vivo 3D tumor microenvironment may lead
to tumor models with predictive response of cancer therapies in patients.
The stiffness and composition of the microenvironment influences cell morphology,
cytoskeletal structure, signaling, and function for many normal and cancer cell types [170, 237,
238]. The stiffness of the ECM increases during the malignant progression of cancer, promoting
more aggressive and metastatic phenotypes in several cancers [11-13]. Prostate tissue stiffness
increases as PCa develops and progresses, with stiffness of 42 kPa for the normal prostate tissue
and 88 kPa for the PCa tumor [14], while the stiffness of mineralized bone in the metastatic niche
is ~106 kPa [239]. The different tissue stiffness during the stages of PCa malignant progression
provide an opportunity to model the stages with different stiffness biomaterial scaffolds.
Chitosan is natural polymer with a similar chemical structure to glycosaminoglycans and
is commonly derived from crustacean shells [21]. Chitosan is widely used due to its beneficial
properties including biocompatibility, biodegradability, and hydrophilicity [240, 241].
Additionally, chitosan is cationic, allowing it to form a PEC with anionic polymers through
electrostatic interactions [23]. PECs provide the benefits of each polymer in the complex, while
limiting their respective drawbacks. Alginate is a natural polymer obtained from brown seaweed
with beneficial biomedical properties like biocompatibility and ionotropic gelation with divalent
cations [24]. Alginate is anionic when dissolved in water and forms PECs with chitosan when
solutions are mixed in the appropriate pH range. CA 3D porous scaffolds were developed for bone
35

tissue engineering [207]. The CA scaffolds supported culture of several cancers [215, 242] and
enriched the cancer stem cell population in several cancers, including PCa [216, 243]. The
interaction of cancer cells with the CA scaffolds promoted cancer stem cell enrichment for several
cancers while poly -caprolactone coated CA scaffolds did not, indicating that the CA material
chemistry influenced the cell response and promoted more malignant cultures than 2D cultures or
3D cultures with synthetic polymer scaffolds [216, 243]. Despite these promising CA scaffold
results, only one composition (4 wt%) was evaluated, leaving the influence of CA scaffold stiffness
unexplored. The CA scaffold processing was optimized [244], providing guidelines to produce
different CA scaffold compositions.
Herein, we present the development of two new CA scaffold compositions (2 wt% and 6
wt%) and the use of those scaffolds, along with 4 wt% CA scaffolds, to assess the influence of CA
scaffold stiffness on PCa response. The three CA scaffold compositions approximate the stiffness
of the stages of PCa malignant progression, including normal prostate tissue, primary PCa tumor,
and bone metastatic niche. Our hypothesis was that CA scaffold cultures will recapitulate the PCa
cell phenotype indicated by expression of biomarkers, including phospho-epidermal growth factor
receptor (pEGFR), LIM domain kinase 1 (LIMK1), prostate specific antigen (PSA) and androgen
receptor (AR), as well as promote mineralization for the osteoblastic cell lines in a stiffness
dependent manner. These biomarkers were selected as they are upregulated in malignant prostate
tissues and correlated with bone metastases [245-248]. Confirming this hypothesis would
demonstrate the link between increased CA scaffold stiffness and PCa characteristics, which is
anticipated based on the stiffening of the tumor microenvironment during progression of PCa. The
physical properties of the CA scaffolds were characterized with mechanical testing, scanning
electron microscopy (SEM) imaging, Fourier Transform Infrared (FTIR) spectroscopy, and
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porosity analysis. PCa was selected as a model cancer as it metastasizes to bone and the CA
scaffolds resemble the bone microenvironment. PCa cell lines, PC-3, C4-2B and 22Rv1 were
selected for culture to provide comparison of 1) functional AR and non-functional AR, and 2)
osteolytic and osteoblastic phenotypes. PCa cells were seeded on the 2, 4, and 6 wt% CA scaffolds
and cultured for 15 d. The PCa cell phenotypes were characterized by Alamar blue assay, SEM,
Alizarin Red staining, immunofluorescence (IF), and qRT-PCR.

3.2. Materials and Methods
3.2.1. Materials
All materials were purchased from Sigma Aldrich (St. Louis, MO) unless otherwise
indicated. Chitosan (practical grade, > 75% deacetylated, MW = 190,000 ‒ 375,000 Da), alginic
acid sodium salt, potassium bromide, Triton X-100 and Alizarin Red were used as received.
Roswell Park Memorial Institute (RPMI) 1640 medium, Ham's F-12K medium, penicillinstreptomycin

(PS), Dulbecco’s phosphate

buffered saline (D-PBS), 0.25% trypsin-

ethylenediaminetetraacetate (EDTA), and Alamar blue reagent were purchased from Fisher
Scientific (Waltham, MA). Accumax was purchased from Innovative Cell Technologies (San
Diego, CA). Fetal bovine serum (FBS) was purchased from Atlanta Biologicals (Flowery Branch,
GA). Human PCa cell lines PC-3, C4-2B and 22Rv1 were purchased from American Type Culture
Collection (ATCC, Manassas, VA) and were maintained according to manufacturer’s instructions.

3.2.2. Scaffold Synthesis
CA scaffolds were produced by adapting a previously published method [244]. Briefly, a
chitosan solution was prepared by dissolving chitosan (2, 4, and 6 wt%) into acetic acid solutions
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(0.5, 1, and 1.5 wt%) prepared in deionized (DI) water. The chitosan solution was mixed with a
Thinky mixer (ARM-310, Thinky USA, Laguna Hills, CA) at 2000 rpm for three min twice. An
alginate solution was prepared by dissolving alginic acid sodium salt (2, 4, and 6 wt%) into DI
water and mixing the solution in a Thinky mixer at 2000 rpm for three min twice. The chitosan
and alginate solutions were aged overnight at room temperature. The solutions were combined and
stirred with a spatula, then mixed with the Thinky mixer at 2000 rpm for five min twice. The CA
solution was cast into molds, refrigerated at 4 °C for 1.5 h, frozen at -20 °C overnight, and
lyophilized for 48 h. The CA scaffolds were cut into 2 mm thick discs and crosslinked with 0.2 M
calcium chloride for 15 min under vacuum. After crosslinking, the scaffolds were washed with DI
water three times to remove any residual calcium chloride. CA scaffolds were sterilized by
immersing in 70% ethanol under vacuum for 15 min twice, followed by three D-PBS washes and
shaking in excess D-PBS overnight.

3.2.3. Mechanical Characterization
Mechanical properties of the CA scaffolds were measured through compression testing of
dry and wet samples (n = 10 per group). The CA scaffolds were cut into 10 mm ×10 mm ×10 mm
cubes and the samples were compressed at rate of 0.4 mm/min to 75% of initial height by AGS-X
mechanical tester (Shimadzu, Japan) with 500 N load cell. The wet samples were crosslinked with
0.2 M CaCl2 solution, washed with D-PBS, and stored in D-PBS until tested. The compressive
stiffness was calculated as the slope of the linear regions of the stress-strain curve (0 – 10% strain,
bulk stiffness; 60 – 80% strain wall stiffness) [249]. The stiffness of patient derived xenografts
(PDX) prostate tumor samples (PDX Live, TM00298, Jackson Laboratory, Bar Harbor, ME) were
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characterized with the same procedures, using six samples (n = 6) prepared as cubes of 3 mm × 3
mm × 3 mm.

3.2.4. FTIR Analysis
The CA scaffolds were assessed with FTIR spectroscopy to evaluate the CA PEC formation.
The scaffolds were cut into fine pieces, then ground with potassium bromide powder using a mortar
and pestle. The mixed power was compressed into a 1 mm thick semi-transparent pellet with a
Quick Press KBr Pellet Kit (International Crystal Lab, Garfield, NJ). The samples were analyzed
with FTIR (Nexus 870, Thermo Nicolet, Waltham, MA) with 1000 scans at 8 cm-1 resolution and
compared to pure chitosan and alginate samples.

3.2.5. Porosity Analysis
Scaffold porosity was measured using a modified liquid displacement method where
isopropanol was used as the displacement liquid [209]. Rectangular samples (10 mm × 10 mm ×
5 mm, n = 5) for each scaffold composition were prepared, the sample dimensions were measured
using a digital micrometer (Mitutoyo), and the scaffold volume (Vi) was calculated. The dry
scaffold weight (Wi) was measured using an electronic analytical balance (ML54T, Mettler Toledo,
Switzerland). The scaffold was immersed in 30 mL of isopropanol with known density (ρi = 0.785
g/mL) under vacuum for 30 min to remove air from the pores. The isopropanol saturated scaffold
was weighed (Wf) and the porosity was calculated (Eqn. 1).
Porosity =

(Wf −Wi )/ρi
Vi
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× 100%

(1)

3.2.6. Cell Seeding
Three cell lines, PC-3, C4-2B, and 22Rv1, were expanded in T-75 cell culture flasks until
70% confluency at 37 °C and 5% CO2 in a fully humidified incubator. PC-3 cells were cultured in
F-12K media, while C4-2B and 22Rv1 cells were cultured in RPMI 1640 media, with both media
containing 10% FBS and 1% PS. The cells were detached from the culture flasks with trypsinEDTA, centrifuged at 200 g, and resuspended in fully supplemented media at 1  106 cells/mL.
The CA scaffolds were placed in 12 well tissue culture plates and seeded dropwise with 100,000
cells in 100 µL of fully supplemented media and incubated at 37 C and 5% CO2 for 1.5 h, then
1.5 mL of fully supplemented media was added to each well. The scaffolds were transferred to
new well plates after 24 h to avoid any effects from cells attached to the bottom of the well.
Samples were cultured for 15 d and the media was changed every other day. Cell seeding efficiency
was calculated by detaching the cells remaining in the initial well plates with trypsin-EDTA
following the procedure described above and cell number was counted with hemocytometer with
n = 4 samples per scaffold composition and cell line.

3.2.7. Alamar Blue Assay
The cell number for the scaffold cultures was quantified at 5, 10, and 15 d with the
Alamar blue assay following the manufacturer’s protocol. Alamar blue solution (10% Alamar
blue reagent in fully supplemented media) was added to each well and the samples were
incubated at 37 °C and 5% CO2 for 1.5 h. The Alamar blue solution was then transferred to a
black 96-well plate to obtain fluorescence values using Cytation 5 cell imaging multi-mode plate
reader (BioTek, Winooski, VT) at excitation wavelength of 560 nm and fluorescence emission
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read at 595 nm. The cell number was calculated using a standard curve prepared with known cell
numbers for each cell line.

3.2.8. SEM Imaging
The CA scaffolds were sputter coated with Pd-Au and imaged with SEM (JSM-6480 JEOL,
Japan). Cultured samples were fixed with 3.7% formaldehyde in D-PBS for 1 h at 37 C. The
samples were washed with D-PBS and stored in D-PBS at 4 °C. The fixed samples were
dehydrated with graded ethanol washes (0%, 30%, 50%, 75%, 85%, 95%, and 100%) with each
ethanol concentration applied three times for a total of 15 min. The samples were freeze dried
overnight and then sputter coated with Pd-Au and SEM imaged.

3.2.9. Immunofluorescence Analysis
Samples were fixed with 3.7% formaldehyde for 1 h at 37 °C, washed with PBS three times
and stored in PBS at 4 °C for histology analysis. The samples were embedded in paraffin and 5
µm sections were cut and mounted on slides, deparaffinized with xylene and ethanol, then
rehydrated in TE buffer. Antibody solutions were prepared in 10% bovine serum albumin (BSA)
solution in D-PBS.
Primary antibodies used include rabbit monoclonal E-cadherin (1:200 dilution, Cell
Signaling Technology, Danvers, MA), rabbit monoclonal pan-actin (1:200 dilution, Cell Signaling
Technology), mouse monoclonal cytokeratin 8 (1:100 dilution, Santa Cruz Biotechnology, Santa
Cruz, CA), rabbit monoclonal androgen receptor (1:50 dilution, Cell Signaling Technology), rabbit
polyclonal anti-osteocalcin (10 g/mL dilution, Abcam, Cambridge, MA), and rabbit monoclonal
phospho-EGF receptor (1:500 dilution, Cell Signaling Technology). The samples were incubated
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with the primary antibodies overnight at room temperature in a sealed box to avoid evaporation.
The samples were washed three times with D-PBS, then the secondary antibodies were added. The
secondary antibodies included fluorescein goat anti-rabbit, DyLight 488 horse anti-mouse,
biotinylated horse anti-rabbit, and Texas Red streptavidin (all 1:200 dilution, all from Vector
Laboratories, Burlingame, CA). The secondary antibodies were incubated at room temperature for
20 min then washed with D-PBS, with the biotin and streptavidin antibodies being applied in two
incubations. The samples were mounted with DAPI Fluoromount-G (SouthernBiotech,
Birmingham, AL). The samples were imaged with a Leica TCS SP5 confocal microscope (Leica,
Buffalo Grove, IL) using the 405 nm, 488 nm and DPSS 561 nm lasers. Protein expression was
quantitated by applying a threshold for each marker based on secondary only controls and average
intensity was divided by cell number with Fiji [250] for at least 6 images per experimental group.

3.2.10. Real Time-Quantitative PCR
Cells were harvested from the scaffolds at 5, 10, and 15 d time points for PCR analysis.
Samples were transferred to a new 12 well plate and 2 mL of Accumax was added to each sample
and shaken for 15 min on an orbital shaker (Scilogex, Rocky Hill, CT) at 125 rpm. After shaking,
the samples were washed with the Accumax solution and the solution was collected in a 50 mL
tube. The steps were repeated with another 2 mL of Accumax and the solution was collected. The
solution was centrifuged at 200 g and the supernatant was aspirated, leaving the cell pellet, which
was resuspended in 1 mL of D-PBS and transferred to a 1.5 mL tube in and centrifuged.
Supernatant was aspirated and cell pellet was frozen at -80 C until use. RNA extraction was
performed with a RNeasy Kit (Qiagen, Germantown, MD) following manufacturer’s protocol.
RNA concentrations were measured with the NanoDrop 1000 spectrophotometer (Thermo
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Scientific, Waltham, MA) and 200 ng of RNA was used for cDNA synthesis. cDNA synthesis was
performed using the high capacity cDNA reverse transcription kit (Applied Biosystems, Waltham,
MA) as per manufacturer’s protocol. Briefly, 200 ng starting RNA was mixed with the kit
components in a 10 L reaction volume and processed in GeneAmp PCR System 9600 (Perkin
Elmer, Waltham, MA) at 25 °C for 10 min, 37 °C for 120 min and 85 °C for 5 min for cDNA
synthesis. RT-PCR samples were prepared by combining cDNA, 2X QuantiTect SYBR green
master-mix (Qiagen), and QuantiTect primers (Qiagen) were used for target genes (AR, PSA,
LIMK) and internal controls (EIF3D and RPL13A), which contained both forward and reverse
primers. QuantStudio 7 (Applied Biosystems) was used for qRT-PCR with the following cycling
conditions: 95 °C for 15 min, followed by 40 cycles at 94 °C for 15 s for renaturation, 55 °C for
30 s for annealing and 72 °C for 30 s for extension, with data collection at the extension step. Data
was normalized to the internal controls and presented as relative fold change in expression
compared with 2D cultures using the Ct method.

3.2.11. Alizarin Red Staining
Additional paraffin sections were cut at 15 µm thickness, mounted on slides, and
deparaffinized. 2D controls were cultured on coverslips, fixed with 3.7% formaldehyde for 1 h at
37 °C, washed with PBS three times and stored in PBS at 4 °C. The samples were stained with 100
µl of 2 wt% Alizarin Red solution at pH 4.2 and incubated in the dark at room temperature for 2
min. The samples were rinsed with DI water, followed by washes in acetone for 20 s, acetonexylene (1:1) solution for 20 s, then cleared in xylene for 5 min, and mounted a coverslip with
mounting media. Brightfield images were obtained using the Cytation 5 cell imaging multi-mode
reader. The intensity of Alizarin Red images was analyzed by applying a threshold based on
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uncultured scaffold controls and average intensity was divided by scaffold area with Fiji [250] for
at least 6 images per experimental group.

3.2.12. Fluorescence Imaging and Cellular Analysis
All data were presented as the mean ± standard deviation (SD) of the mean. Statistical
significance was set at p < 0.05 and tested with ANOVA and t-tests (Microsoft Excel).

3.3. Results and Discussion
3.3.1. CA Scaffold Characterization
3D porous CA scaffolds were produced with different concentrations to approximate the
stiffness of the stages of PCa malignant progression, including normal prostate tissue, primary PCa
tumor, and bone metastatic niche. The appearance of the CA scaffolds is shown in dry and wet
conditions (Fig. 7a). All three CA scaffold compositions had a highly porous and interconnected
pore structure (Fig. 7b). The CA scaffolds had pore sizes of 253 ± 52 μm, 210 ± 21 μm and 217 ±
33 μm for 2, 4, and 6 wt% CA, respectively (Fig. 7c). The 2 wt% CA scaffolds had a statistically
significant difference (p < 0.05) in pore size compared with the 4 wt% and 6 wt% CA scaffolds.
The CA scaffold pore size was measured in the dry state, so the pore size in the hydrated CA
scaffolds will be larger by the percent volume change between hydrated and dry CA scaffolds,
assuming that the scaffolds swell isotropically. The percent volume change between hydrated and
dry CA scaffolds was 13.17%, 16.63%, and 25.64%, for the 2, 4, and 6 wt% CA scaffolds,
respectively. The 2, 4, and 6 wt% CA scaffolds had porosities of 90.78  0.6%, 93.16 ±2.2%, and
91.44 ± 2.0% porosity, respectively (Fig. 7c). The 2 wt% CA scaffolds had a statistically
significant difference (p < 0.05) in porosity compared with the 4 wt% CA scaffolds. The scaffolds
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were formed through the freeze casting process, where the CA solution was cast and frozen, then
lyophilized to sublimate the ice, resulting in a porous scaffold with interconnected pores. The
percent porosity, pore morphology, and pore size were influenced by the nucleation rate and the
size of ice crystals, which depends on the cooling rate of the solution [251]. All three scaffold
compositions were frozen at the same temperature (-20 C), which contributed to the similar pore
sizes and percent porosity.

Figure 8 CA scaffold properties. a) Appearance of 2, 4, and 6 wt% CA scaffolds discs in dry (top)
and wet (bottom) states. b) Pore morphology of 2, 4, and 6 wt% CA scaffolds, low (top) and high
(bottom) magnification images. c) Percent porosity, average pore size and compressive strength
for 2, 4, and 6 wt% CA scaffolds. d) Wall stiffness of 2, 4, and 6 wt% CA scaffolds, along with
PDX tumor stiffness, in dry and wet conditions. The * denotes statistically significant differences
(p < 0.05).
The stiffness (Figs. 7d and S2) and compressive strength (Supplemental Table 1) of the
three CA scaffold compositions were measured in dry and wet states. Two stiffness values, bulk
stiffness and wall stiffness, were obtained due to the porous structure of the CA scaffolds. The
bulk stiffness is obtained from the initial linear slope of the stress-strain curve and indicates the
stiffness of compacting the pores of the scaffold, while the wall stiffness is obtained from the final
45

linear slope of the stress-strain curve where the scaffold porosity has been compacted and the
material comprising the scaffold is being evaluated [249]. Our focus is on the wall stiffness of the
scaffolds, as this is the stiffness that the cells will sense, while the bulk stiffness values are reported
in Fig. S2. The wall stiffness of the dry 2, 4, and 6 wt% CA scaffolds is 0.812 ±0.115 MPa, 2.579
± 0.313 MPa, and 7.154 ± 0.977 MPa, respectively. The wall stiffness of the wet 2, 4, and 6 wt%
CA scaffolds is 63.9 ± 7.54 kPa, 2.365 ± 0.320 MPa, and 3.30 ± 0.415 MPa, repectively. The
stiffness values for the 2, 4, and 6 wt% CA scaffolds were significantly different (p < 0.05) in both
dry and wet conditions (Fig. 7d). The compressive strength of the dry 2, 4, and 6 wt% CA scaffolds
was 0.138 ±0.013 MPa, 0.483 ±0.061 MPa, and 1.154 ±0.119 MPa, respectively (Table S1). The
compressive strength of the wet 2, 4, and 6 wt% CA scaffolds was 7.75 ±2.32 kPa, 203.31 ±46.63
kPa, and 403.13 ± 25.44 kPa, respectively (Table S1). The compressive strength values for the 2,
4, and 6 wt% CA scaffolds were significantly different (p < 0.05) in both dry and wet conditions.
The increased scaffold concentrations from 2 to 6 wt% CA led to a significant increase in scaffold
stiffness and compressive strength in both dry and wet conditions (Figs. 7d, S2; Table S1). The
stiffness and compressive strength of PCa PDX tumors were measured with the same method and
were 2.447  0.101 MPa and 276.11  34.56 kPa (Figs. 7d, S2), respectively, indicating that the
wet 4 wt% CA scaffolds most closely approximated the PCa tumor stiffness out of the three CA
scaffold compositions. While the normal prostate tissue and bone were not measured with the same
technique for comparison to the scaffolds, the 2 wt% CA scaffolds resembled the stiffness of the
native prostate tissue and the 6 wt% CA scaffolds approximated the stiffness of the bone
microenvironment. Various methods, including shear wave elastography and ultrasound, have
been reported to measure the stiffness and change in stiffness of prostate tissue, as increases in
prostate stiffness are correlated with carcinogenesis [14]. While these different methods have been
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used to assess the prostate stiffness, it is challenging to correlate data from different techniques
without introducing artifacts, due to different sample sizes, different methods, and other test
restrictions.
The PEC formation in the CA scaffolds was assessed with FTIR analysis. The FTIR spectra
for chitosan, alginate, and the three CA scaffold compositions are presented in Fig. S3.
Characteristic peaks in the alginate spectra include the peaks at 1600 cm-1 (COO- antisymmetric
stretch), 2920 cm-1 (C-H stretch), and 3430 cm-1 (O-H stretch). Characteristic peaks in the chitosan
spectra includes the peaks at 2900 cm-1 (C-H stretch), 1650 cm-1 (amide I, C = O), and 1590 cm-1
(amide II, N-H). The chitosan used for scaffold synthesis is partially deacetylated ( 75%
deacetylated), resulting in the two amide peaks at 1650 cm-1 and 1590 cm-1 [207]. CA PEC
formation is indicated by the combination of amide I (1650 cm-1) and N-H bending of amide II
(1590 cm-1) chitosan peaks and the COO- antisymmetric (1600 cm-1) alginate peak into one peak
at 1630 cm-1, which is shown on the 2, 4, and 6 wt% CA spectra [252]. Similar findings have been
reported that the formation of this new peak indicates CA PEC formation, although the peak
wavelength varies between reports [207, 252, 253]. The verification of PEC formation for each
scaffold composition confirms that the CA molecules interacted. The formation of CA PECs
provides greater scaffold stability than a mixture of the two molecules without complex formation.
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Figure 9 PCa cell growth on CA scaffolds. Alamar blue assay results for (a) PC-3, (b) C4-2B and
(c) 22Rv1 on 2, 4, and 6 wt% CA scaffolds at 5, 10, and 15 d, * denotes statistically significant
differences (p < 0.05).
3.3.2 PCa Cell Lines Respond Differentially To Scaffold Stiffness
Three PCa cell lines, PC-3, C4-2B and 22Rv1, were cultured on the 2, 4, and 6 wt% CA
scaffold compositions. The three PCa cell lines have different profiles: PC-3 cells were derived
from a lumbar metastasis and are androgen independent; C4-2B cells were derived from a bone
metastasis of the LNCaP parental line and has a full length AR; and 22Rv1 cells were derived from
a human prostatic carcinoma xenograft, CWR22R, and has a truncated AR [254]. Additionally,
the PC-3 cells display osteolytic behavior, while the C4-2B and 22Rv1 cells display osteoblastic
behavior [90, 255]. These three cell lines provided a comparison of PCa osteolytic and osteoblastic
phenotypes and androgen responses that are observed in human patients to examine on the three
CA scaffold compositions. The three cell lines had a cell seeding efficiency of > 80% on all
scaffold compositions (Table S2). The cell number in the CA scaffold cultures was assessed at 5,
10, and 15 d time points (Fig. 8). At 5 d, either the 2 wt% or 4 wt% CA scaffolds had the greatest
cell number, while the 6 wt% CA had the lowest cell number for all three cell lines. At 10 d, 4 wt%
CA had the greatest cell number for C4-2B, while 6 wt% CA had the greatest cell number for PC3 and 22Rv1. At 15 d, 6 wt% CA has the greatest cell number for all cell lines. A maximum cell
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number appears to have been reached at 10 d for all cell lines, followed by consistent or decreased
cell numbers in all cultures at 15 d. This decreased cell number at 15 d could be due to several
factors, including the presence of necrotic cells in spheroids, metabolic re-programming of the
cells affecting the Alamar blue assay readings, or other factors. Decreased Ki-67 expression was
observed in all cell lines between 10 and 15 d (Fig. S4), indicating decreased cell proliferation and
suggesting the formation of necrotic regions or cell cycle arrest within the tumor spheroids. The
cell number was proportional with CA scaffold stiffness only at 15 d for all three cell lines, where
6 wt% CA had greatest cell number, followed by 4 wt% and 2 wt% CA. This result of cell number
increasing proportionally with scaffold stiffness needs further investigation to examine the cell
number over longer culture times. Other than at 15 d, there were no clear trends in the PCa cell
growth with scaffold stiffness. Stiffness independent growth has been observed for PC-3 and
22Rv1 cells in 2D cultures [256]. The PC-3 and 22Rv1 cells showed differences in the growth
with respect to scaffold stiffness during the 15 d culture, demonstrating different responses of the
cells in 3D porous CA scaffolds compared to 2D cultures. All the CA scaffold compositions
supported PCa growth, but there was not a strong difference in cell number with respect to scaffold
stiffness.

Figure 10 PCa cell morphology on CA scaffolds. SEM images of PC-3 (a), C4-2B (b), and 22Rv1
(c) cells on 2, 4, and 6 wt% CA scaffolds at 5, 10, and 15 d time points, scale bar is 25 microns.
The white arrows denote hole-like features that formed in the 22Rv1 spheroids.
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The cell morphology of the three cell lines on the CA scaffolds at 5, 10, and 15 d time
points is presented in Figure 3. All three cell lines had a rounded cell morphology on the 2, 4, and
6 wt% CA scaffolds. Despite the common rounded cell morphology, there were differences in the
cell appearance in the CA scaffold cultures. The PC-3 cells formed grape-like cell clusters, while
C4-2B and 22Rv1 cells formed multicellular spheroids (Fig. 9). The PC-3 cell morphology was
not influenced by the CA scaffold stiffness, as the cells formed clusters on all scaffold
compositions and maintained a consistent appearance throughout the cultures (Fig. 9a). The PC-3
cell morphology may have been influenced by the CA scaffold composition, as others have
demonstrated the influence of 1 integrin in promoting a stellate morphology and its inhibition
resulting in a grape-like cell morphology [257]. The CA scaffolds are comprised of
polysaccharides and do not inherently provide binding sites for 1 integrin, potentially
contributing to the observed grape-like cell clusters. C4-2B cells formed spheroids by 5 d, with
the greatest number of spheroids observed on 2 wt% CA, and fewer spheroids on the 4 wt% and 6
wt% CA scaffolds (Fig. 9b). The C4-2B spheroid size decreased with increasing scaffold
concentration from 2 to 6 wt% CA, particularly at 5 d. The C4-2B spheroids developed an
increasingly rough appearance with increasing culture time from 5 to 15 d. The 6 wt% CA C4-2B
cultures had a much rougher spheroid surface than the 2 and 4 wt% CA cultures at 10 d. 22Rv1
cells formed spheroids with a smooth surface on all CA scaffold compositions (Fig. 9c). 22Rv1
cultures on 6 wt% CA at 10 and 15 d had much smoother spheroid surfaces than 2 and 4 wt% CA.
The 22Rv1 spheroids had hole-like features present on the spheroids in the 4 wt% and 6 wt% CA
scaffold cultures, with the most prominent features observed in the 6 wt% CA cultures at 15 d,
indicated with white arrows in Fig. 3. It is unclear what these hole-like features are, but they may
be the formation of duct-like structures within the spheroids.
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3.3.3 Evaluation of PCa Cell Interaction With CA Scaffolds
The PCa cells cultured on the CA scaffolds were characterized with IF staining to assess
the cell-cell and the cell-material interactions. The PCa cells were analyzed for E-cadherin
expression to characterize the cell-cell interaction in the 3D cultures. The CA scaffold cultured
cells for all three cell lines displayed altered cell morphologies compared with the 2D cultures: the
cells had rounded morphologies in the CA scaffolds and spread morphologies in 2D cultures. The
rounded cell morphologies observed in the CA scaffold cultures (Fig. 9) suggested the
upregulation of E-cadherin compared to 2D cultures. The E-cadherin expression increased for PC3 and 22Rv1 cells in the CA scaffolds, while it decreased for C4-2B cells in the CA scaffolds (Fig.
10). While the C4-2B cells formed spheroids in CA scaffolds, the lower E-cadherin expression
compared to 2D cultures indicates that another mechanism may be promoting spheroid formation.
PC-3 cells vary their E-cadherin expression in suspension cultures compared with adherent
cultures, with cell attachment and cell spreading needed for dynamic regulation of E-cadherin and
N-cadherin expression [258]. The involvement of 1 integrin mediated cell adhesions to the matrix
is a key component in promoting N-cadherin expression [258]. The 1 integrin is the most
commonly occurring integrin heterodimer that promotes interaction with collagen and fibronectin
[259]. It has been shown to support anchorage-independent growth of PCa cells and may influence
the size of PCa colonies grown in Matrigel [259]. These results demonstrate that integrin binding
and focal adhesion activation may be needed to promote N-cadherin expression and downregulate
E-cadherin expression in the CA scaffolds.
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Figure 11 E-cadherin expression for PCa cultures. Immunofluorescence images of 2D, 2, 4, and
6 wt% CA cultures at 10 d. E-cadherin (E-cad) is stained green and nuclei are stained blue. Scale
bars are 15 microns.
To further evaluate the PCa interaction with the CA scaffolds, the actin cytoskeleton was
evaluated with IF. All 3D cultures had greater actin expression than 2D cultures (Fig. 11). Actin
was localized in the cytoplasm surrounding the nucleus in all 3D cultures, not in stress fibers. This
indicates that the PCa cells are not engaging integrins or forming FAs to bind to the CA scaffold
matrix. The focal adhesion development is a multistep process that begins upon cell contact with
the matrix, followed by cellular contraction that organizes the actin fibers and promotes focal
adhesion reinforcements, finally resulting in a mature focal adhesion with pronounced actin stress
fibers [260]. The FAs enable force transmission from the matrix to the cell and the
mechanotransduction cellular responses [261]. These results suggest that another molecule is
promoting adhesion to the CA scaffold, which is not surprising as the CA scaffolds do not contain
proteins, only polysaccharides, so no ligands for integrins are present. Further experiments are
needed to address the mechanism for cell adhesion to the CA scaffolds. Such studies may examine
the influence of CD44 or other HA binding proteins, since the CA scaffolds are comprised of
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molecules that resemble the HA structure. Elucidating this cell adhesion mechanism to the CA
scaffolds will provide insights into the PCa responses observed with increasing CA scaffold
stiffness. Additionally, experiments incorporating proteins or peptides on to the CA scaffolds
could promote integrin binding and focal adhesion formation.

Figure 12 Actin expression for PCa cultures. Immunofluorescence images of 2D, 2, 4, and 6 wt%
CA cultures at 10 d. Actin is stained red and nuclei are stained blue. Scale bars are 15 microns.
3.3.4. Evaluation of PCa Phenotype in Scaffold Cultures
IF staining and qRT-PCR were used to evaluate the expression of biomarkers to quantify
the phenotype of the CA scaffold cultures. IF assessed the expression of pEGFR, AR, and
cytokeratin 8 (KRT8) in the samples. KRT8 was examined in all three cell lines, while AR was
only examined in C4-2B and 22Rv1 as PC-3 has an inactive AR. As a result, PC-3 was examined
with pEGFR in place of AR. EGFR is regulated in normal cells but constantly stimulated in tumor
cells, where it can facilitate cancer cell growth, metastasis, and invasion [262]. EGFR
overexpression was shown to be correlated with the hormone refractory PCa phenotype [263] and
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increased EGFR expression was observed in the majority of androgen independent PCa patients
[264]. Androgen is the primary molecule that stimulates PCa progression by promoting
proliferation and preventing apoptosis via binding to and activating AR [265]. AR is present in the
majority of primary and metastatic PCa cases, spanning many stages, grades, and even hormone
refractory cancers [266]. The AR provides a primary target for PCa treatment until the PCa
becomes androgen independent, often due mutation into a constitutively active AR mutant [267].
KRT8 is an intermediate filament protein found in normal prostate epithelial cells, but it is also
found on the cell membrane of some carcinoma cells [268]. KRT8 expression was used as an
epithelial cell marker.

Figure 13 Expression of characteristic proteins for PC-3, C4-2B, and 22Rv1 cells. a) Comparison
of characteristic protein expression for all PCa cell lines at 10 d. KRT8 is shown in red and nuclei
are shown in blue for all cell lines. The green color is AR for C4-2B and 22Rv1, while it is pEGFR
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for PC-3. b) Relative florescent intensity of pEGFR normalized by 2D intensity for PC-3, c)
Relative florescent intensity of AR normalized by 2D intensity for C4-2B, d) Relative florescent
intensity of pEGFR normalized by 2D intensity for 22Rv1, * denotes statistically significant
differences (p < 0.05).
All PC-3 scaffold cultures had greater pEGFR expression compared with 2D (Fig. 12). The
4 wt% CA cultures had the greatest expression of pEGFR among the scaffold cultures, while 6 wt%
CA cultures had lowest expression, which was similar to the 2D cultures (Fig. 12). The PC-3
scaffold cultures had similar KRT8 expression among the CA compositions, with all scaffold
compositions showing KRT8 expression indicating the epithelial phenotype in cells in scaffold
cultures. The C4-2B 2D cultures had the greatest AR expression and AR expression was
downregulated in the scaffold cultures, with significant differences in expression between 2D and
scaffold cultures (Fig. 12). There was no significant difference in AR expression between the
scaffold cultures. The scaffold cultures demonstrated KRT8 expression in all scaffold culture
conditions indicating epithelial phenotype of C4-2B cells grown in in CA scaffolds (Fig. 12). The
22Rv1 cultures had similar AR and KRT8 expression between the four groups (Fig. 12). The 4 wt%
CA scaffold cultures had the greatest AR expression compared to the other cultures. The KRT8
expression for 22Rv1 was relatively consistent among the cultures (Fig. 12). Individual IF images
for each cell line and each scaffold composition are presented in Fig. S7-S9. Our IF results show
no significant changes in cell phenotype for PC-3 and 22Rv1, but a reduced AR expression in C42B cells in CA scaffolds.
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Figure 14 qRT-PCR analysis of characteristic gene expression. a) LIM kinase 1 expression of PC3 cells on 2, 4, and 6 wt% CA scaffolds at 10 d. b) PSA and c) AR expression for C4-2B and 22Rv1
cells on 2, 4, and 6 wt% CA scaffolds at 10 d. The * denotes statistically significant differences (p
< 0.05).
The gene expression for all three cell lines and culture conditions was evaluated at 10 d
with qRT-PCR to assess the preservation of PCa cell characteristics (Fig. 13). C4-2B and 22Rv1
cell lines were evaluated for expression of AR and PSA mRNAs, while PC-3 was tested for
expression of LIMK1 mRNA. One of the characteristics of C4-2B and 22Rv1 cell lines is that both
cell lines express AR, which is a transcription factor. AR specifically stimulates transcription of
PSA mRNA, hence expression of PSA represents the activation status of the AR. PSA is also the
clinical gold standard biomarker for PCa diagnosis [269]. PSA expression is a marker for PCa
progression as PSA downregulates cell apoptosis and increases cell proliferation [270]. LIMK1 is
an enzyme that regulates the actin cytoskeleton and is overexpressed in PCa [271], specifically in
PC-3 cells. LIMK1 is also critical for the PCa invasive growth [272]. Because PC-3 cells are highly
aggressive androgen-independent PCa cells, LIMK1 expression was used as a marker for
aggressive phenotype of PCa cells.
The PC-3 CA scaffold cultures had downregulated LIMK1 expression compared to the 2D
cultures, with statistically significant differences between 2D and each scaffold composition (Fig.
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10a). Among the scaffold cultures, LIMK1 expression showed a significant increase in 6 wt%
cultures compared to 2 wt% cultures. PSA expression demonstrated different trends for C4-2B and
22Rv1 cultures with respect to stiffness (Fig. 13b). PSA expression did not change in C4-2B
scaffold cultures at 2 wt% and 4 wt% CA compared with 2D cultures (Fig. 13b). The PSA
expression for the 6 wt% CA cultures was significantly lower than the 2D and 2 wt% and 4 wt%
CA scaffold cultures. All 22Rv1 CA scaffold cultures had upregulated PSA expression compared
with 2D cultures (Fig. 13b) with a maximum increase at 6 wt% CA compared to 2D cultures.
Additionally, 22Rv1 cultures had statistically significant increase in PSA expression in 6 wt% CA
compared to 2 wt% and 4 wt% CA scaffold cultures. There were no significant differences in AR
expression observed for C4-2B and 22Rv1 scaffold cultures. The C4-2B AR expression was
downregulated in the scaffold cultures compared to 2D cultures, whereas no significant change in
AR expression in 22Rv1 cells was observed between 2D and 3D cultures. The C4-2B and 22Rv1
AR expression PCR results support the results of IF expression analysis. The marker expression
analysis with IF and qRT-PCR demonstrated different responses to scaffold stiffness for each cell
line. PC-3 cells demonstrated upregulation of pEGFR expression and downregulation of LIMK1
expression in the CA scaffolds. C4-2B cultures had downregulation of PSA and AR expression in
3D cultures, while 22Rv1 cultures had similar expression of AR between 2D and CA scaffold
cultures and PSA expression was upregulated in the 6 wt% CA scaffolds. Collectively, the protein
and gene expression results demonstrated that the CA scaffold cultures supported expression of
phenotypic markers different expression profiles for each cell line.
Characterization of phenotype demonstrated a shift in marker expression for PC-3 cells
grown in CA scaffolds. There was a loss of expression of LIMK1 but a gain in expression of
pEGFR in PC-3 cells in 2 wt% and 4 wt% CA. Collectively, these observations suggest that PC-3
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cells maintain their aggressive phenotype in 3D cultures. Interestingly, the PC-3 E-cadherin and
actin expression was upregulated in CA scaffold cultures, which may be related the
downregulation of LIMK1 expression. Further experiments are needed to explore this potential
connection for CA scaffold cultured PC-3 cells. Similarly, there is no significant change in AR
expression and activity in C4-2B and 22Rv1 cells grown in 2 wt% and 4 wt% CA scaffolds except
PSA expression in 22Rv1 cells grown in 6 wt% CA scaffold culture. Similar PSA expression
results for C4-2B and 22Rv1 cultures have been reported in the literature. Downregulation of PSA
expression like in the C4-2B cultures was observed where LNCaP cells were cultured in rotary
wall vessels as 3D organoids, but the PSA expression was restored when the 3D organoids were
co-cultured with human prostate fibroblast cells [273]. This demonstrates the importance of the
stromal cell contribution to PCa malignancy that cannot be recreated with cultures only comprised
of cancer cells. Upregulation of PSA expression like in the 22Rv1 cultures was observed where
LNCaP cells cultured on collagen-based scaffolds had higher PSA expression compared with 2D
cultures [274].

3.3.5. CA Scaffolds Promote Mineralization In Osteoblastic PCa Cell Lines
Osteoblastic and osteolytic responses of PCa cells have been demonstrated both in vitro
[275] and in vivo [276-278]. These responses arise due to factors produced by PCa cells that can
act directly or indirectly to induce an osteogenic response [276, 279, 280]. PCa cells grown in 2D
culture in normal growth media do not mineralize (Fig. S10). However, C4-2B cells were shown
to mineralize in 2D cultures with osteogenic media (containing 10 mM -glycerophosphate and
50 mg/ml L-ascorbic acid) [281]. To evaluate whether CA scaffold culture may promote
mineralization of C4-2B cells in normal growth media and to determine if the rough appearance
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of the C4-2B spheroids was related to mineralization, Alizarin Red staining and osteocalcin IF
were performed for all groups to assess the presence of calcium phosphates and bone matrix
proteins. Alizarin Red staining indicates the presence of calcium deposits and is commonly used
to assess the osteogenic differentiation of mesenchymal stem cells.

Figure 15 Alizarin Red staining to assess mineralization. a) Comparison of PC-3, C4-2B and
22Rv1 cell lines on 4 wt% CA scaffolds at 10 d. Dark red staining denotes mineralization, indicated
with arrows. b) Quantification of Alizarin Red staining in scaffolds compared to uncultured
scaffold controls, * denotes statistically significant differences (p < 0.05).
Positive Alizarin Red staining in C4-2B and 22Rv1 samples was observed (Fig. 14),
denoted by the bright red deposits and arrows, while no positive staining was observed for PC-3.
The faint red color observed in 2, 4 and 6 wt% scaffolds for PC-3 cultures and in regions of the
other cell line samples is background staining of the scaffold, not positive staining for
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mineralization. The background staining of the scaffold was determined by comparing the samples
to uncultured scaffold controls that were stained with Alizarin Red (Fig. S10).

Figure 16 Osteocalcin expression confirms presence of bone matrix. a) Comparison of osteocalcin
expression (red) between PC-3, C4-2B, and 22Rv1 cell lines at 10 d. Nuclei are stained blue, scale
bars are 15 microns. b) Relative florescent intensity of osteocalcin normalized by 2D sample
intensity for each cell line. The * denotes statistically significant differences (p < 0.05).
To confirm that the observed mineralization was bone mineral and not pathological
calcification, osteocalcin expression was assessed with IF. Osteocalcin is a non-collagenous
protein found in bone matrix that plays a role in bone mineralization [282]. Analysis of the
osteocalcin expression for PC-3, C4-2B and 22Rv1 cell lines on 2, 4, and 6 wt% CA scaffolds (Fig.
15) demonstrated that C4-2B and 22Rv1 scaffold cultures expressed osteocalcin, while PC-3
cultures did not. None of the 2D cultures for any cell line expressed osteocalcin, demonstrating
that the osteocalcin expression was promoted by scaffold culture. This confirms the presence of
mineralized bone matrix for the osteoblastic C4-2B and 22Rv1 cultures and indicates that the
osteolytic PC-3 cultures did not exhibit mineralized bone matrix. Osteocalcin expression
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demonstrates the presence of bone matrix and confirms that the mineralization observed with SEM
and Alizarin Red analysis is bone mineral and not pathological calcification.
The mineralization results agree with the literature. PC-3 cells induced osteoblast-like cells
to express osteoclastogenesis factors after co-culture [275] or when cultured with PC-3
conditioned media [283]. The osteolytic behavior of PC-3 cells was demonstrated by injecting PC3 cells into humanized tissue engineered bone constructs implanted in mice, where the bone was
resorbed [255]. Conversely, C4-2B cells enhanced the mineralization of hematopoietic progenitor
cells [90]. Additionally, the mineralization in the C4-2B cultures and the osteoblastic phenotype
may contribute to the downregulation of PSA expression observed in the C4-2B scaffold cultures.
PSA expression for C4-2 cells was downregulated when cultured with conditioned media (CM)
from osteoblast cell lines due to soluble factors in CM [284].
This study demonstrated that osteoblastic and osteolytic PCa cell lines responded in
different manners to CA scaffolds with different stiffnesses. Further research is needed to evaluate
the effect of scaffold stiffness on PCa cells when co-cultured with fibroblasts or other cells found
in the PCa tumor microenvironment. Additionally, incorporation of proteins into or conjugation
on to the CA scaffolds may provide a greater response to scaffold stiffness by enabling integrin
binding. Since the CA scaffold cultures revealed differences in the PCa cell line responses, the CA
scaffolds have potential for use to evaluate patient-derived primary PCa cells. These CA scaffold
cultures may be used to determine the expression of phenotypic markers and screen prospective
chemotherapies, allowing these cultures to supplement pathology data from tumor biopsies.
Further research is needed to determine if CA scaffold cultures recapitulate the responses of the
patient tumor to therapies, which would potentially enable their use in personalized cancer
treatment.
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3.4. Conclusions
Three CA scaffold compositions were prepared that exhibited increasing stiffness with
increasing scaffold concentration and approximated the stiffness of the microenvironmental stages
of PCa malignant progression. The 4 wt% CA scaffolds showed a similar stiffness to prostate PDX
tumors. PCa cells grown on the 3D scaffolds had rounded morphology: specifically, AR expressing
C4-2B and 22Rv1 cells formed multicellular spheroids, while AR negative PC-3 cells formed
clusters. PCa cells grown in 3D culture showed expression of markers that confirm their epithelial
status and cell phenotypes. Additionally, the osteoblastic C4-2B and 22Rv1 cells showed
mineralization and osteocalcin expression when grown in all CA scaffold compositions tested,
which was not observed in the osteolytic PC-3 cells. This observation demonstrates that CA
scaffold cultures may discern between osteoblastic and osteolytic PCa phenotypes. These results
suggest that CA scaffold cultures could be used to identify PCa phenotypic characteristics, with
potential applications for in vitro anti-cancer drug screening of clinical samples.

62

CHAPTER 4: 3D POROUS CHITOSAN-CHONDROITIN SULFATE
SCAFFOLDS PROMOTE EPITHELIAL TO MESENCHYMAL
TRANSITION IN PROSTATE CANCER CELLS
Xu, K., Wang Z., Copland J.A., Chakrabarti R., Florczyk, S.J. Biomaterials 2020; 254: 120126

4.1. Introduction
PCa is a commonly diagnosed cancer and is estimated to be the second leading cause of
death for men in the US in 2019 [1]. Primary PCa is curable, but metastatic PCa has poor prognosis.
Androgen-deprivation therapy is often used to treat metastatic PCa, however, it frequently
becomes androgen-insensitive and progresses to castration-resistant PCa [5, 6], an advanced form
of PCa with few treatments [7]. CS is a sulfated GAG that is found in normal prostate tissue and
is overexpressed in primary PCa [28] and is further upregulated in the peritumoral stroma of
metastatic PCa [29], indicating that it is a marker for poor PCa prognosis [30].
The TME contains a heterogeneous cell population consisting of tumor cells and stromal
cells including fibroblasts, endothelial cells, and immune cells [8]. The TME also includes the
tumor stoma, which consists of the ECM, signaling molecules, and stromal cells [285, 286]. The
ECM is a 3D network composed of macromolecules, including collagen, proteoglycans, and HA
[101, 286]. The ECM is a major component of the TME and ECM remodeling is often deregulated
in cancer development, causing changes in ECM stiffness and composition that can promote
cancer metastasis [10]. EMT is an important step in metastatic progression, where epithelial cells
acquire mesenchymal characteristics [48] and increase cellular plasticity, motility, drug resistance,
and cancer stem cell features [49, 50]. ECM plays an important role in EMT [287], as periostin
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activates Snail through P-Akt pathway in PCa [130] and ECM stiffening cooperates with TGFβ to
induce breast cancer EMT [288].
2D cultures exhibit cell morphologies, gene expression, and signal transduction that do not
represent in vivo conditions [15-17]. 3D cultures, including multicellular spheroids [20] and
biomaterial scaffolds [19], have been developed to overcome these limitations of 2D cultures [18].
3D cultures in biomaterial scaffolds, including Matrigel [195], PLG [202] and chitosan-HA (CHA) [209], have been shown to better mimic the in vivo TME than 2D cultures. Additionally, 3D
cultures promote enhanced drug resistance [18, 19], suggesting that 3D cultures provide more
predictive responses of in vivo performance for cancer therapies than 2D cultures. Chitosan has a
chemical structure that resembles GAGs [289] and is a commonly used biomaterial due to its
biodegradability, biocompatibility, hydrophilicity, and low immunogenicity [22]. Chitosan is
cationic when dissolved in solution, enabling formation of PECs with anionic polymers through
electrostatic interactions. CA [242] and C-HA 3D porous scaffolds [209] have been evaluated for
TME applications. CA scaffold cultures promoted cancer stem cell enrichment [216, 243] and
bone mineral deposition by osteoblastic PCa cells [290]. However, alginate is bioinert and lacks
cell adhesion ligands, requiring alginate to be modified to promote cell adhesion [213, 214]. CS
has greater bioactivity than alginate as it is a GAG that occurs in ECM and is correlated with PCa
progression. Additionally, CS is anionic and it forms PECs with chitosan that can be formed into
scaffolds. Chitosan may swell [207] and CS is highly soluble in water [291], preventing either
material from independently forming stable scaffolds.
In this work, 3D porous C-CS scaffolds were developed and evaluated for in vitro PCa
culture. Three C-CS scaffold compositions, 4 w/v% chitosan with 0.1, 0.5, and 1.0 w/v% CS, were
produced to evaluate the effect of CS concentrations on PCa EMT. C-CS scaffolds were prepared
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by mixing chitosan and CS solutions to form PECs, followed by freeze-casting and lyophilization.
Our hypothesis was that the increasing CS concentration in C-CS scaffolds will promote EMT in
PCa cells indicated by upregulated EMT marker expression and increased drug resistance. The CCS scaffold material properties were characterized with mechanical testing, SEM, FTIR
spectroscopy, porosity analysis, pore size measurement, viscosity measurement, and swelling test.
Two PCa cell lines, PC-3 and 22Rv1, were cultured on the C-CS scaffolds to evaluate PCa cell
growth. These PCa cell lines were selected because of their phenotypic differences, where PC-3
cells have a non-functional androgen receptor and an osteolytic phenotype, while 22Rv1 cells have
a functional androgen receptor and an osteoblastic phenotype [90, 254, 255]. These phenotypic
differences provide more comprehensive insights about the PCa interaction with the scaffolds and
the effect of CS concentration on EMT marker expression. PC-3 and 22Rv1 cells were cultured on
C-CS scaffolds for 10 d and characterized with Alamar Blue assay, SEM, IF imaging, qRT-PCR,
and docetaxel (DTX) resistance.

4.2. Materials and Methods
4.2.1. Materials
All materials were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise
indicated. CS (chondroitin sulfate sodium salt, from shark cartilage), chitosan (practical grade, >
75% deacetylated, MW = 190,000 ‒ 375,000 Da), Triton X-100, BSA, dimethyl sulfoxide
(DMSO), isopropanol, and potassium bromide were used as received. Ham's F-12K medium,
RPMI 1640 medium, PS, 0.25% trypsin-EDTA, D-PBS, TRIzol, and Alamar Blue reagent were
purchased from Fisher Scientific (Waltham, MA). FBS was purchased from Atlanta Biologicals
(Flowery Branch, GA). TE buffer was purchased from Corning (Corning, NY). Mouse
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monoclonal CD44 and rabbit monoclonal vimentin primary antibodies were purchased from Cell
Signaling Technology (Danvers, MA). DyLight 488 horse anti-mouse, biotinylated anti-rabbit
and Texas Red streptavidin secondary antibodies were purchased from Vector Laboratories
(Burlingame, CA). DAPI Fluoromount-G was purchased from SouthernBiotech (Birmingham,
AL). RNeasy Mini Kit was purchased from Qiagen (Germantown, MD). Bio-Rad iScript™
cDNA Synthesis Kit was purchased from Bio-Rad (Hercules, CA). All primers used for qRTPCR, including GAPDH, E-cadherin, N-cadherin, Snail, and MMP-2, were purchased from
Integrated DNA Technologies (Coralville, Iowa). Human PCa cell lines, PC-3 and 22Rv1, were
purchased from American Type Culture Collection (ATCC, Manassas, VA) and maintained
according to the manufacturer’s instructions.

4.2.2. Scaffold Synthesis
Three C-CS scaffold compositions were prepared with 4 w/v% chitosan and 0.1, 0.5, and
1.0 w/v% CS. The scaffolds were named based on their composition with scaffolds containing 4
w/v% chitosan and 0.1 w/v% CS named 4-0.1 and the other two C-CS scaffold compositions were
named 4-0.5 and 4-1. A 4 w/v% chitosan solution was prepared by dissolving chitosan in 1 w/v%
acetic acid solution and mixed using a Thinky mixer (ARM-310, Thinky USA, Laguna Hills, CA) at 2000
rpm for three min twice. CS solutions were prepared by dissolving CS (0.1, 0.5, and 1 w/v%) in DI

water and mixed using a Thinky mixer at 2000 rpm for three min twice. After aging overnight at
room temperature, chitosan solution was added into CS solution and stirred with a spatula, then
mixed using the Thinky mixer at 2000 rpm for 10 min twice. The C-CS solution was cast into 24well plate molds, refrigerated at 4 °C for 1 h, frozen at -20 °C overnight, and lyophilized with a
freeze dryer (FreezeMobile 25 EL, Virtis, Warminster, PA) for 48 h. The dry C-CS scaffolds were
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cut into 1 mm thick discs and neutralized with 1 M sodium hydroxide under vacuum for 45 min.
The scaffolds were washed with DI water three times to remove any residual base, followed by
immersing in 70 v/v% ethanol under vacuum for 15 min twice for sterilization and washed with
sterile D-PBS for three times. Sterile scaffolds were stored in D-PBS until use.

4.2.3. Viscosity Measurement
C-CS PEC solution viscosity was measured with a Haake Viscotester iQ Rheometer
(Thermo Scientific, Waltham, MA). A CC25 DIN/Ti measuring geometry was used and samples
(n = 5 per group) were tested at 20 °C maintained by a Peltier temperature module with heat
exchanger iQ. Each measurement lasted 1000 s with an increasing shear rate up to 100/s.

4.2.4. Porosity Measurement
C-CS scaffold porosity was measured by a modified liquid displacement method [209].
Scaffolds (n = 6 per group) were cut into a rectangular shape (10 mm × 10 mm × 5 mm),
dimensions were measured using a digital micrometer (Mitutoyo, Japan) and the scaffold volume
(Vi) was calculated. The dry scaffold weight (Wi) was measured using an electronic analytical
balance (ML54T, Mettler Toledo, Switzerland). The scaffolds were immersed in 30 mL of
isopropanol with density (ρi) of 0.785 g/mL under vacuum overnight to fill pores with isopropanol.
The saturated scaffold was weighed (Wf) and the porosity was calculated (Eqn. 2).
Porosity =

(Wf −Wi )/ρi
Vi
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× 100%

(2)

4.2.5. SEM Imaging
C-CS scaffolds were sputter coated with Au and imaged with SEM (JSM-6480, JEOL,
Japan). Cultured C-CS scaffolds at 3, 7 and 10 d were fixed with 3.7 v/v% formaldehyde for 1 h
at 37 °C. The fixed samples were washed with D-PBS three times and stored in D-PBS at 4 °C.
The samples were dehydrated with graded ethanol washes (0, 30, 50, 75, 95, and 100 v/v%), with
each wash applied three times for a total of 15 min. The dehydrated samples were freeze dried
overnight, sputter coated with Au, and imaged with SEM (JSM-6480).

4.2.6. Pore Size Measurement
Scaffold pore size was analyzed with SEM images at 50 × magnification using a
modification of ASTM standard E112-13 for determining average grain size. A template of 5
parallel lines spanning the SEM images with 18 mm spacing was used. The line length was
calibrated to microns using the SEM image scale bar. The number of pores intersected by the lines
was counted and the line length was divided by the number of pores to quantify the pore size.
Average pore size was calculated from five lines per image (n = 3) for a total of fifteen
measurements per scaffold composition.

4.2.7. Mechanical Characterization
C-CS scaffold mechanical properties were measured in compression for dry and wet
samples (n = 8 per group). The scaffolds were cut into 10 mm × 10 mm × 10 mm cubes and
compressed at rate of 0.4 mm/min to 75% of initial height using an AGS-X mechanical tester
(Shimadzu, Japan) with 500 N load cell. The wet samples were neutralized and stored in D-PBS
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before testing. Bulk stiffness (0 – 10% strain) and wall stiffness (60 – 80% strain) were calculated
as the slope of the linear elastic and densification regime, respectively [249, 292].

4.2.8. Swelling Test
C-CS scaffold discs with 15 mm diameter and 1 mm thickness for each composition were
neutralized and sterilized as described above. After sterilization, scaffolds (n = 5 per group) were
kept in a sterile 50 mL tube and frozen at -20 °C for 3 h, then freeze-dried overnight to produce
dry samples for initial dimension measurements. Two lines at 90  angles were marked on each
dry scaffold disc with an alcohol-proof marker to ensure that the scaffolds were measured in the
same locations at each time point. The samples were immersed in D-PBS and incubated at 37 °C
and 5% CO2 for 10 d. The lengths were measured at 0, 0.5, 1.5, 4, 6, 24, 48, 72, and 240 h along
the marked lines using a digital micrometer (Mitutoyo). The measurements were normalized to the
dry scaffold dimensions at 0 h.

4.2.9. FTIR Spectroscopy
FTIR spectroscopy was used to evaluate C-CS PEC formation. C-CS scaffolds were cut
into small pieces, then ground with potassium bromide powder using a mortar and pestle. A Quick
Press KBr Pellet Kit (International Crystal Lab, Garfield, NJ) was used to press the ground powder
to a 1 mm thick semi-transparent pellet. The samples were analyzed with FTIR (Nexus 870,
Thermo Nicolet, Waltham, MA) with 1000 scans at 8 cm-1 resolution and compared to pure
chitosan and CS samples.
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4.2.10. Cell Seeding
PC-3 and 22Rv1 cells were cultured in complete media at 37 °C and 5% CO2 in a
humidified incubator. The complete media for PC-3 cells was Ham's F-12K media containing 10%
FBS and 1% PS, while for 22Rv1 cells it was RPMI-1640 media containing 10% FBS and 1% PS.
Cells were detached using trypsin-EDTA, centrifuged at 200 × g for 5 min, and resuspended in
complete media at 5 × 105 cells/mL. Cells (50,000 in 100 μL in complete media) were seeded
dropwise onto C-CS discs with 15 mm diameter and 1 mm thickness in 24-well tissue culture
plates. The scaffolds were incubated at 37 °C and 5% CO2 for 1.5 h before 1 mL of complete media
was added to each well. Samples were transferred to new 24-well plates after 24 h to avoid any
effects from cells attached to the bottom of the well. Samples were cultured for 10 d and the media
was changed every other day.

4.2.11. Alamar Blue Assay
Alamar Blue assay was used to quantify the cell number following the manufacturer’s
protocol at 3, 7, and 10 d. Alamar Blue solution was prepared as 10 v/v% Alamar blue reagent in
complete media and 1 mL was added to each sample (n = 3), then incubated for 1.5 h at 37 °C and
5% CO2. After incubation, 250 μl Alamar Blue solution was taken from the well in duplicate and
transferred to a black 96-well plate to obtain fluorescence intensity using Cytation 5 cell imaging
multi-mode plate reader (BioTek, Winooski, VT) at excitation wavelength of 560 nm and
fluorescence emission read at 595 nm. The intensities were then converted into cell numbers using
a standard curve generated with known cell numbers for each cell line.
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4.2.12. Immunofluorescence Imaging
The fixed 10 d samples were mounted in paraffin and 5 µm thick sections were cut using
a microtome. Sections were placed onto slides, baked in an oven at 60 °C for 30 min,
deparaffinized with xylene, and dehydrated by ethanol. The samples were rehydrated with TE
buffer in a pressure cooker for 14 min for antigen retrieval. Blocking buffer and antibody dilution
buffer was 10% BSA in D-PBS. Samples were incubated with blocking buffer for 30 min at room
temperature then washed with D-PBS three times. Primary antibodies, including mouse
monoclonal CD44 (1:400 dilution) and rabbit monoclonal vimentin (1:100 dilution), were added
and incubated at room temperature for 1 h. The samples were washed with D-PBS three times and
secondary antibodies, including DyLight 488 horse anti-mouse, biotinylated anti-rabbit, and Texas
Red streptavidin (all 1:200 dilution), were added and incubated for 20 min at room temperature.
Samples were washed with D-PBS three times then mounted with a coverslip using DAPI
Fluoromount-G. Samples were imaged with Leica TCS SP8 (Leica, Buffalo Grove, IL) confocal
microscope using 405 nm, 488 nm, and DPSS 561 nm lasers. Fiji [293] was used to quantify the
intensity of protein expression (n = 7 images per group) by setting a constant threshold for each
marker based on 2D control. The fluorescence intensity was divided by the cell number in the
image to get the average intensity value and normalized to 2D.

4.2.13. Real Time qRT-PCR
C-CS scaffolds cultured for 10 d were washed with D-PBS three times to remove residual
media prior to RNA extraction. TRIzol containing 1.4 M sodium chloride was added to the samples
for 30 s, then the solution was collected in a 1.5 mL tube and mixed with 200 µL of chloroform.
The mixture was centrifuged at 12,000 × g for 20 min at 4 C and the top aqueous phase was
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transferred to a new 1.5 mL tube. The solution was mixed with equal volume of isopropanol and
centrifuged at 12,000 × g for 20 min at 4 C. The supernatant was removed, and 1 mL of
isopropanol was added to repeat the process once more. After centrifugation, the supernatant was
aspirated and 1 mL of 100% ethanol was added, followed by centrifuging at 12,000 × g for 5 min
at 4 C. The supernatant was removed, and RNeasy Mini Kit was used for further RNA purification
following the manufacturer’s protocol. Extracted RNA was synthesized to cDNA using the BioRad iScript™ cDNA Synthesis Kit following the manufacturer’s protocol. Primers used for qRTPCR were GAPDH, E-cadherin, N-cadherin, Snail, and MMP-2 (Supplemental Table 1). qRTPCR assessment was performed using Mx3000 Multiplex Quantitative PCR System (Stratagene,
San Diego, CA) with the following cycle conditions: 95 °C for 10 min, 40 cycles of 30 s at 94 °C
for denaturation, 60 s at 55 °C for annealing, and 30 s at 72 °C in for extension. Data was
normalized to the GAPDH internal control and presented as relative fold change compared with
2D cultures using the ∆∆Ct method.

4.2.14. Docetaxel Drug Response
96-well sized C-CS scaffolds were punched out from 24-well sized scaffold discs using a
5 mm diameter biopsy punch (Integra Miltex, Plainsboro, NJ), then neutralized and sterilized as
described previously. Cells (12,000/well) were seeded onto the C-CS scaffolds in 96-well plates.
For 2D cultures, cells (6,000/well) were seeded after 5 d of scaffold culture to avoid overconfluency. The cultures were treated with DTX at 6 d: PC-3 were treated with 60 nM DTX and
22Rv1 were treated with 10 nM DTX using DMSO as vehicle (n = 4 per group). These DTX
concentrations induced cytotoxicity in 2D cultures during preliminary testing to determine the dose.
Fully supplemented media containing DMSO only was added to vehicle control samples (n = 4
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per group). Cell number was measured with Alamar Blue assay after 72 h of drug treatment and
viability was determined by evaluating sample cell number relative to vehicle cell number.

4.2.15. Statistical Analysis
All data were presented as the mean ± S) of the mean. Statistical significance was set at p
< 0.05 and tested with ANOVA and t-tests (Microsoft Excel). The biological characterization was
performed on two rounds of cultures with at least n = 3 samples per analysis per culture.

4.3.Results and Discussion
4.3.1. C-CS Scaffold Properties
3D porous C-CS scaffolds were developed for PCa culture. Three CS concentrations were
evaluated due to increasing CS concentration with PCa progression [28, 29]. All of the C-CS
scaffold compositions had a similar appearance, with a white color when dry that became
transparent when wet (Fig. 16a). The C-CS scaffolds had highly interconnected pore structure (Fig.
16b) and the average pore size significantly decreased from 4-0.1 to 4-1 scaffolds, with values of
165.51  22.54 m, 153.21  17.06 m, and 142.97  16.97 m for 4-0.1, 4-0.5, and 4-1 C-CS
scaffolds, respectively (Fig. 16c). The scaffold porosities significantly increased from 4-0.1 to 41 scaffolds, with values of 90.24  0.91%, 92.81  0.3%, and 95.13  1.33% for 4-0.1, 4-0.5, and
4-1 scaffolds, respectively (Fig. 16d). The solution viscosities were 4.54  0.23 Pas, 6.39  0.22
Pas, and 11.85  0.60 Pas for 4-0.1, 4-0.5, and 4-1 scaffolds, respectively (Fig. 16e). The
significant increase in viscosity is due to greater PEC formation with increasing CS concentration,
as observed with increasing C-CS solution turbidity (Fig. 16f), resulting in greater polymer chain
entanglement. The increased C-CS solution viscosity with greater CS concentration contributes to
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the smaller pore size in 4-1 scaffolds compared to 4-0.1 scaffolds. The increased viscosity limits
the motion of polymer molecules during freezing and mechanically hinders ice growth, leading to
smaller ice crystal size and smaller pore size [230, 231].

Figure 17 C-CS scaffold properties. a) Appearance of all C-CS scaffold compositions as in bulk
(top), dry (middle), and wet (bottom). b) C-CS scaffold pore morphology. SEM images for low (top)
and high (bottom) magnification. C-CS scaffold pore size (c) and porosity (d). e) C-CS solution
viscosity. f) C-CS solutions become more turbid with increasing CS concentration, indicating more
PEC formation. C-CS scaffold wall stiffness for dry (g) and wet (h) conditions.
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The C-CS scaffold stiffness and strength were measured in compression under dry and wet
conditions. The stress–strain curve for a cellular solid in compression can be divided into three
regimes: linear elastic, plateau, and densification [292]. The bulk stiffness is measured in the linear
elastic regime, where the pores are compacted [249]. After all of the pores are crushed, the stiffness
of the material, or wall stiffness, is measured in the densification regime [249]. The wall stiffness
of C-CS scaffolds is the stiffness that the cells will sense as they are in contact with the scaffold
pore walls. The wall stiffness for dry scaffolds (Fig. 16g) was 1101.16 ± 216.18 kPa, 1186.90 ±
136.99 kPa, and 1129.72 ± 202.40 kPa for 4-0.1, 4-0.5, and 4-1 scaffolds, respectively. The wall
stiffness for wet scaffolds (Fig. 16h) was 500.23 ±151.21 kPa, 520.58 ±151.16 kPa and 484.82 ±
50.96 kPa for 4-0.1, 4-0.5 and 4-1, respectively. The C-CS scaffold stiffness was lower than PCa
PDX tumor stiffness of 2447.04  101.16 kPa that was measured with compressive testing in our
previous study [290]. PDX tumor was denser than the porous C-CS scaffolds as it included cells
and ECM, likely contributing to its higher stiffness than porous C-CS scaffolds. While the C-CS
scaffold stiffness did not match the PDX tumor, it exceeded the stiffness of normal prostate tissue,
which is 42 kPa measured with shear wave elastography [14]. The similar wall stiffness among CCS scaffolds eliminates the influence of stiffness on cell response, allowing the influence of CS
content to be examined without bias of scaffold stiffness. The bulk stiffness of dry scaffolds was
438.11 ± 53.96 kPa, 365.33 ± 10.22 kPa, and 276.64 ± 43.32 kPa for 4-0.1, 4-0.5, and 4-1,
respectively. The bulk stiffness of wet scaffolds was 8.66 ±0.79 kPa, 8.59 ±1.08 kPa, and 6.83 ±
0.78 kPa for 4-0.1, 4-0.5, and 4-1, respectively. The compressive strength of dry scaffolds was
142.26 ±24.6 kPa, 180.55 ±20.2 kPa, and 170.8 ±37.0 kPa for 4-0.1, 4-0.5, and 4-1, respectively.
The compressive strength of wet scaffolds was 46.82 ± 22.2 kPa, 83.53 ± 32.49 kPa, and 110.63
± 34.33 kPa for 4-0.1, 4-0.5, and 4-1, respectively. The C-CS scaffold bulk stiffness decreased
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with increasing CS concentration. The bulk stiffness is measured when pores are compressed and
is affected by pore features [249]. The larger pore size and greater porosity compromises the
scaffold bulk stiffness because of a larger void volume within a consistent scaffold volume [200,
294]. The 4-1 scaffolds had the lowest bulk stiffness in wet and dry conditions, along with the
smallest pore size and the highest porosity compared with other scaffolds, suggesting that porosity
had a greater influence on C-CS scaffold bulk stiffness than pore size. The increasing compressive
strength with increasing CS concentration was expected since more material is present in the
scaffolds with greater CS concentration.
C-CS PEC formation was analyzed with FTIR and compared with chitosan and CS spectra
(Fig. 17a). The characteristic peaks for chitosan are 1650 cm-1 (amide I), 1580 cm-1 (amide II), and
1390 cm-1 (C - N stretching) [295]. The two amide peaks occur due to using partially deacetylated
chitosan [207]. The characteristic peaks in the CS spectrum include 1650 cm-1 (amide I), 1420 cm1

(C - O stretching), 1380 cm-1 (O - H variable-angle vibration) and 1220 cm-1 (S = O stretching)

[295]. The weakening of the COO- related peaks at 1420 cm-1 and 1380 cm-1 in the C-CS spectra
relative to the CS spectrum indicated that carboxyl groups reacted with chitosan [296]. The amide
I peak at 1650 cm-1 and amide II at 1580 cm-1 on the chitosan spectrum shifted to 1630 cm-1 and
1550 cm-1, respectively, on the C-CS spectra. The combination of these changes in characteristic
peaks for chitosan and CS in the C-CS spectra suggests C-CS PEC formation through amino and
carboxyl group interaction [295, 297]. PEC formation promotes the C-CS scaffold stability. The
C-CS scaffold stability was evaluated with a swelling test, where scaffolds were incubated in DPBS for 10 d (Fig. 17b, c). All three C-CS scaffold compositions swelled to ~106% of the diameter
of dry conditions within 1 h and maintained the dimensions without deformation or visible
degradation over 10 d. The C-CS scaffold stability is promising for an in vitro culture platform.
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Figure 18 C-CS scaffolds contain PECs that promote scaffold stability. a) FTIR spectra for three
C-CS scaffold compositions, pure chitosan, and pure chondroitin sulfate were shown. PEC
formation was indicated by the shift of 1650 cm-1 (amide I) and 1580 cm-1 (amide II) peaks in
chitosan spectra to 1630 cm-1 and 1550 cm-1 in all C-CS spectra . C-CS scaffold swelling test in
D-PBS for 6 h (b) and 3 10 wks d (c), normalized to original dry diameter.
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Figure 19 C-CS scaffolds support PCa cell growth. Alamar blue assay results for (a) PC-3, (b)
22Rv1 on 4-0.1, 4-0.5 and 4-1 C-CS scaffolds at 3, 7, and 10 d. The * denotes statistically
significant differences (p < 0.05).
4.3.2. C-CS Scaffolds Support PCa Cell Growth
PCa cells were cultured on C-CS scaffolds to evaluate their growth and response to the CS
concentrations. PC-3 and 22Rv1 cells were cultured on C-CS scaffolds for 10 d and cell numbers
were analyzed with Alamar Blue assay at 3, 7, and 10 d. PC-3 cells cultured on 4-1 scaffolds had
the greatest cell number throughout the 10 d cultures, while the 4-0.5 scaffolds had significantly
higher cell numbers compared with the 4-0.1 scaffolds at 3 d, but similar cell numbers at 7 d and
10 d (Fig. 18a). 22Rv1 cells cultured on 4-1 scaffolds had the greatest cell numbers throughout the
10 d cultures, while 4-0.5 scaffolds had similar cell numbers as the 4-0.1 scaffolds at 3 d, but
significantly higher cell numbers at 7 d and 10 d (Fig. 18b). Collectively, all three C-CS scaffold
compositions supported PCa cell growth. The 4-1 scaffolds had the greatest cell number for both
PC-3 and 22Rv1 throughout the cultures. 22Rv1 cell number increased with increasing CS
concentration, indicating that CS promoted 22Rv1 cell growth. We found that PC-3, 22Rv1, and
C4-2B demonstrated stiffness-independent cell growth when cultured on CA scaffolds with
different stiffness [290]. The effect of CS on PCa cell growth compared with our recent study with
78

CA scaffolds suggests that CS concentration has a greater effect on PCa cell growth than stiffness
in chitosan-based scaffolds. PCa cell morphology was assessed with SEM imaging at 10 d. PC-3
and 22Rv1 had different cell morphologies on the C-CS scaffolds, with grape-like clusters for PC3 and multicellular spheroids for 22Rv1 (Fig 19). There were no apparent differences in cell
morphology between C-CS scaffold compositions. The spherical PCa cell morphology on 3D CCS scaffolds better mimics in vivo cell morphology than 2D culture, which promoted a polygonal
cell morphology.

Figure 20 PC-3 and 22Rv1 cell morphology on C-CS scaffolds. SEM images of PC-3 (top) and
22Rv1 cells (bottom) cultured on C-CS scaffolds at 10 d. Scale bar is 25 microns.
4.3.3. C-CS Scaffolds Upregulate EMT Marker Expression
EMT promotes PCa metastasis through enhanced cell motility and invasiveness [49, 50].
Two EMT markers, CD44 and vimentin, were characterized with IF on 10 d samples. CD44 is a
transmembrane glycoprotein and its overexpression is associated with PCa EMT and distant
metastasis [298]. Vimentin is an intermediate filament protein that plays a critical role with
changes in cell shape, adhesion, and motility during EMT [299]. 22Rv1 cultures on 4-1 scaffolds
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had the greatest CD44 expression among all scaffolds, while 22Rv1 on 4-0.1 and 4-0.5 scaffolds
had similar CD44 expression, and all scaffolds had significantly greater CD44 expression than 2D
(Fig. 20). PC-3 cells had strong CD44 expression on 2D cultures and C-CS scaffolds (Fig. 21a).
Relative intensity measurements indicated that 4-1 scaffolds had significantly greater CD44
expression compared with the other cultures, but no significant differences were found among the
4-0.1 scaffolds, 4-0.5 scaffolds, and 2D cultures (Fig. 21b). All PC-3 cultures had strong CD44
expression, which denotes its aggressive state. Vimentin was only analyzed for PC-3 since 22Rv1
does not express vimentin [300, 301]. PC-3 cultures on 4-1 scaffolds had the greatest vimentin
expression compared with the other C-CS scaffolds and 2D cultures (Fig. 21a). The relative
intensity measurements indicated that PC-3 vimentin expression increased with increasing CS
concentration, as the 4-1 scaffolds had the greatest expression, followed by the 4-0.5 scaffolds, 40.1 scaffolds, and 2D cultures (Fig. 21b). The 4-1 scaffold cultures had the greatest CD44
expression for PC-3 and 22Rv1 that may be due to increased cell-scaffold interaction since CD44
can bind to CS through the carbohydrate-binding domain [302, 303]. 22Rv1 had similar CD44
expression on 4-0.1 and 4-0.5 scaffolds, potentially indicating a CS concentration threshold to
upregulate CD44 expression. The upregulation of CD44 expression could induce increased
vimentin expression, since they are positively correlated [298]. Vimentin has a strong influence
on cell motility: upregulation of vimentin promotes cell mobility [304] and its downregulation in
androgen independent PCa cells decreased the cell invasiveness [305]. 2D cultured PC-3 cells
demonstrated heterogeneous vimentin expression, as some cells did not have positive vimentin
expression while other cells did. However, PC-3 cultures on all C-CS scaffold compositions had
strong and homogenous vimentin expression, suggesting that C-CS scaffolds upregulated the PC3 vimentin expression compared with 2D cultures.
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Figure 21 CD44 expression is upregulated in 22Rv1 C-CS scaffold cultures. a)
Immunofluorescence images of CD44 (green) and nuclei (blue) in 2D and C-CS cultures at 10 d.
Scale bars are 15 microns. b) Relative CD44 fluorescence intensity normalized by 2D intensity
and number of nuclei present in the image. The * denotes statistically significant differences (p <
0.05).

Figure 22 Vimentin is upregulated while CD44 expression is consistent for PC-3 C-CS scaffold
cultures. a) Immunofluorescence images of CD44 (green), vimentin (red), and nuclei (blue) in 2D
and C-CS cultures at 10 d. Scale bars are 15 microns. White arrows indicate cells that have lower
vimentin expression compared with other 2D cells. Scale bars are 15 microns. b) Relative CD44
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and vimentin fluorescence intensity normalized by 2D intensity and number of nuclei present in
the image. The * denotes statistically significant differences (p < 0.05).

The gene expression of EMT markers, E-cadherin, N-cadherin, Snail, and MMP-2, was
evaluated for PC-3 and 22Rv1 cultures on C-CS scaffolds with qRT-PCR at 10 d. E-cadherin and
N-cadherin are transmembrane glycoproteins that mediate cell-cell adhesion, where E-cadherin is
mainly expressed in epithelial cells [306] and N-cadherin is commonly expressed in mesenchymal
cells [307]. The downregulation of E-cadherin and upregulation of N-cadherin is known as the
cadherin switch and is a characteristic of EMT that promotes cell motility and cancer metastasis
[308, 309]. There was no significant difference in E-cadherin expression for PC-3 cultures on CCS scaffolds compared with 2D (Fig. 22a). PC-3 cultures on 4-0.1 and 4-1 scaffolds had similar
N-cadherin expression and were significantly greater than 4-0.5 scaffolds and 2D cultures, but the
expression level was not substantially upregulated (Fig. 22a). 22Rv1 cultures on all three C-CS
scaffolds had downregulated E-cadherin expression compared with 2D cultures, with no
significant differences between scaffolds (Fig. 22b). 22Rv1 cultures had upregulated N-cadherin
expression with increasing CS concentration, where 4-1 scaffolds had the greatest N-cadherin
expression, followed by the 4-0.5 scaffolds, and the 4-0.1 scaffolds had similar expression as 2D
cultures. Highly metastatic PC-3 cells inherently express low levels of E-cadherin and high levels
of N-cadherin [307, 310], therefore, it was not surprising to find similar E-cadherin and N-cadherin
expression among all PC-3 cultures. 22Rv1 C-CS scaffold cultures had downregulated E-cadherin
and upregulated N-cadherin expression compared with 2D cultures, suggesting that C-CS scaffold
culture induced the cadherin switch in 22Rv1.
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Figure 23 C-CS scaffolds promote EMT gene expression. qRT-PCR analysis of E-cadherin, Ncadherin, Snail and MMP-2 expression for PC-3 (a) and 22Rv1 (b) cells cultured on 2D and CCS scaffolds at 10 d. The * denotes statistically significant differences (p < 0.05).

Snail is a transcription factor that modulates EMT by downregulating cell adhesion and
upregulating cell migration through MAPK pathway [311, 312]. Snail expression was upregulated
for both PC-3 and 22Rv1 on all C-CS scaffolds compared to 2D cultures. PC-3 cultures on 4-0.1
and 4-1 scaffolds had no significant difference in Snail expression and both cultures had
significantly greater Snail expression than the 4-0.5 scaffolds (Fig. 22a). 22Rv1 cultures on C-CS
scaffolds had upregulated Snail expression compared with 2D cultures, with the 4-1 scaffolds
having significantly greater expression than 4-0.1 and 4-0.5 scaffolds (Fig. 22b). MMP-2 plays an
important role in cancer invasion and metastasis by breaking down ECM components, such as type
I collagen and laminin [313]. All PC-3 and 22Rv1 C-CS scaffold cultures had upregulated MMP2 expression compared with 2D cultures. PC-3 cultures on all C-CS scaffold compositions had
upregulation of MMP-2 expression compared to 2D cultures, and the expression on 4-1 scaffold
was significantly higher than 4-0.1 and 4-0.5 scaffolds (Fig. 22a). 22Rv1 cultures on C-CS
scaffolds had upregulated MMP-2 expression with increasing CS concentration, where 4-1
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scaffolds had the greatest MMP-2 expression, followed by 4-0.5 and 4-0.1 scaffolds (Fig. 22b).
Snail expression indicates PCa aggressiveness, as Snail expression increased with PCa progression
from benign to metastatic [314] and immunohistochemical staining of Snail it related to Gleason
grade [315]. Both PC-3 and 22Rv1 C-CS scaffold cultures had upregulated Snail expression
compared with 2D cultures, which agreed with a similar study where TRAMP-C2 cells cultured
in CA scaffolds had upregulated Snail expression compared with 2D cultures [316]. MMP-2 is
positively associated with PCa progression and metastasis [317, 318]. Upregulation of MMP-2
expression with increasing CS concentration for 22Rv1 suggests that CS plays an important role
in PCa EMT and metastasis. Collectively, the upregulation of EMT markers in C-CS scaffold
cultures compared with 2D cultures indicated that the C-CS scaffolds promoted PCa
aggressiveness. Expression of several EMT markers varied with the CS concentration, which
indicated that CS played an important role in PCa EMT. The C-CS scaffold cultures were evaluated
for DTX drug resistance as a functional assay to determine if EMT promoted drug resistance.

4.3.4. C-CS Scaffolds Promote Drug Resistance
The DTX drug resistance of PCa cells cultured on C-CS scaffolds was evaluated compared
to 2D cultures. Drug resistance is a hallmark of cells that have undergone EMT and is typically
increased in 3D cultures. PC-3 and 22Rv1 cultures were treated with DTX for 72 h. The cell
viabilities for both cell lines on C-CS scaffold cultures increased with increasing CS concentration.
PC-3 cultures in 4-0.1, 4-0.5 and 4-1 scaffolds had 37.37 ±22.18%, 80.59 ±17.33%, and 91.24 ±
11.20% viability of the vehicle control, respectively, and were all significantly higher than 2D
viability, 25.84 ±3.30%. The 22Rv1 cultures in 4-0.1, 4-0.5, and 4-1 scaffolds had 66.03 ±13.75%,
71.83 ± 15.96%, and 92.21 ± 29.92% of the viability of vehicle controls, respectively, while 2D
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cultures had only 17.69 ±5.58% viability (Fig. 23b). Collectively, PC-3 and 22Rv1 cultures on CCS scaffolds had greater DTX drug resistance than 2D cultures. These results agree with the
literature, where C4-2B and LNCaP 3D multicellular tumor spheroid cultures showed greater DTX
resistance compared with 2D cultures [319]. The PC-3 and 22Rv1 drug resistance increased from
2D cultures to C-CS scaffold cultures and increased with increasing CS concentration, which is
likely due to the upregulated EMT marker expression, since EMT promotes drug resistance [320,
321]. The correlation between EMT marker expression and drug resistance had been demonstrated
in PCa, where DTX-resistant PCa cell lines, DU-145R and PC-3R, had lower E-cadherin
expression and higher vimentin expression than parental cell lines and the inhibition of EMT
inducer ZEB1 in DU-145R and PC-3R significantly increased the DTX sensitivity [322].

Figure 24 C-CS scaffold culture promotes DTX resistance. PC-3 (a) and 22Rv1 (b) cell viability
after DTX treatment of C-CS scaffolds and 2D cultures for 72 h. The results were normalized to
the vehicle control for each group. The * denotes statistically significant differences (p < 0.05).

This study demonstrated that C-CS scaffolds supported PC-3 and 22Rv1 cell growth and
promoted EMT and drug resistance. The increasing CS concentration promoted upregulated EMT
marker expression and drug resistance for both cell lines. The 4-1 C-CS scaffolds are a promising
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candidate for an in vitro PCa platform with the potential for drug screening applications. Further
C-CS scaffold development will examine C-CS scaffold performance in vivo and the influence of
greater CS concentrations on cell response. Additionally, the C-CS scaffolds could be modified
with ECM components, like HA and type I collagen, mixed into the scaffold or conjugated onto
the scaffold. Strong HA expression in PCa tumor stroma is correlated with high Gleason score and
indicated poor outcome for PCa patients [323], suggesting that HA may play an important role in
PCa progression. While the PCa cells demonstrated strong growth on the C-CS scaffolds, the
scaffolds do not contain any proteins for integrin binding, which may limit cell adhesion and alter
the cell response. Type I collagen is abundant in ECM and promotes cell adhesion through integrin
binding, making it a commonly used biomaterial in 3D scaffolds. Incorporating HA and type I
collagen in C-CS scaffolds will enable the scaffolds to better reproduce the prostate ECM in vitro
and serve as an enhanced platform for PCa in vitro research. 3D biomaterial scaffolds also need to
approximate the ECM mechanical properties in addition to mimicking the ECM composition to
promote the greatest cell response. The tissue stiffness influences PCa development and
progression, as it increases from normal prostate tissue to primary PCa [14]. The C-CS scaffold
stiffness can be altered to better mimic the stiffness of different PCa stages by changing the
chitosan concentration. However, our recent study demonstrated that CA scaffold stiffness did not
affect PCa proliferation or marker expression [290], indicating that protein incorporation into the
chitosan-based scaffolds is needed to enhance cell-material interaction and promote
mechanotransduction. Further development of the C-CS scaffolds will enhance the cell response
and enable their use as a drug screening platform for patient-derived PCa cells and to evaluate
potential chemotherapies.
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4.4. Conclusions
3D porous C-CS scaffolds were developed for PCa culture. Three C-CS scaffold
compositions with different CS concentrations were evaluated to determine the effect of CS
concentration on PCa EMT. All C-CS scaffold compositions had similar wall stiffness despite their
different CS concentrations. The scaffold pore size decreased and porosity increased with
increasing CS concentration. The C-CS scaffolds were evaluated with PC-3 and 22Rv1 cultures
for 10 d. All C-CS scaffolds supported PCa cell growth, where PC-3 and 22Rv1 cultures on 4-1
scaffolds had greatest cell number and 22Rv1 cell number increased with increasing CS
concentration. EMT marker expression was upregulated in C-CS scaffold cultures compared with
2D cultures. The PC-3 vimentin expression and 22Rv1 N-cadherin and MMP-2 expression
increased with increasing CS concentration. The C-CS scaffold cultures had greater DTX
resistance than 2D cultures and both PC-3 and 22Rv1 drug resistance increased with increasing
CS concentration. No phenotypic differences were observed between the cell lines cultured on CCS scaffolds. These results indicate that C-CS scaffolds, particularly 4-1 composition, recapitulate
in vivo molecular and phenotypic aspects of aggressive PCa and that this preclinical model may
be appropriate as an in vitro PCa platform for drug screening.
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CHAPTER 5: FROZEN FILMS: POROUS THIN FILMS FOR IN VITRO
CULTURE
5.1 Introduction
Although the previous CA and C-CS scaffolds provided more insights on PCa, there are
many challenges with performing and analyzing 3D cell cultures, including complicated cell
seeding process, difficulties with imaging, and challenges on downstream analysis. For examples,
the RNA extraction and cell number measurement for hydrogel and 3D porous scaffold 3D culture
are very complicated since the cells are encapsulated in the hydrogel. The material could also
influence the quality of results, since material debris could mix with the cells and influence the
extraction process. Researchers have to modify commercial RNA isolation kit protocols to be
suitable for their materials [324, 325]. However, those modified procedures failed on CA and CCS scaffolds, and an optimized protocol had to be developed for each individual scaffold
composition to get a good quality of RNA for qPCR. 3D culture also has challenges with
microscope observation and imaging, since the cells are on different focal planes in 3D culture and
cannot all be in focus. Harvesting and recovering live cells from 3D culture for downstream
analysis, like flow cytometry, is also very difficult since the material debris will mix with cells and
impede the analysis. These challenges of 3D cell cultures have limited the applications in
pharmaceutical companies for drug development.
In this project, a new biomaterial substrate, called Frozen Films, was developed. Frozen
Films are a 3D culture platform that is as easy to use as 2D cultures. Frozen Films with three
thickness, 20 µm, 60 µm, and 200 µm, were produced with 2 w/v% chitosan solution (C) or 2 w/v%
C mixed with collagen (Col). The samples were named as “composition-thickness”, like C-20 for
chitosan 20 µm thickness. Scaffolds and air-dry films made with same compositions were used as
88

control groups. Commercialized products, ultra-low attachment (ULA) plates, Matrigel and tissue
culture polystyrene (TCP) were also used a control. Material characterizations were performed
using SEM images for surface structure, microscope for sample thickness and dynamic mechanical
analysis (DMA) for stiffness. The potential applications of Frozen Films were investigated,
including drug screening using prostate cancer cells (C4-2B), immunotherapy development using
lung cancer cell (A549) and tissue engineering using mesenchymal stem cells (MSCs).

5.2 Materials and Methods
5.2.1. Materials
All materials were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise
indicated. Chitosan (practical grade, > 75% deacetylated, MW = 190,000 ‒ 375,000 Da), Triton
X-100, BSA, dimethyl sulfoxide (DMSO), were used as received. Ham's F-12K medium,
Minimum Essential Medium (MEM), RPMI 1640 medium, PS, 0.25% trypsin-EDTA, D-PBS,
TRIzol, and Alamar Blue reagent were purchased from Fisher Scientific (Waltham, MA). FBS
was purchased from Atlanta Biologicals (Flowery Branch, GA). DAPI Fluoromount-G was
purchased from SouthernBiotech (Birmingham, AL). RNeasy Mini Kit was purchased from
Qiagen (Germantown, MD). Bio-Rad iScript™ cDNA Synthesis Kit was purchased from Bio-Rad
(Hercules, CA). All primers used for qRT-PCR, including GAPDH, E-cadherin, N-cadherin, Snail,
and MMP-2, were purchased from Integrated DNA Technologies (Coralville, Iowa). Human PCa
cell lines, PC-3 and 22Rv1, were purchased from American Type Culture Collection (ATCC,
Manassas, VA) and maintained according to the manufacturer’s instructions.
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5.2.2 Sample Fabrication
C solutions (2 w/v%) were prepared by dissolving chitosan in 1 w/v% acetic acid solution
and mixed with a Thinky mixer (ARM-310) at 2000 rpm for three min twice. After aging overnight
at room temperature, 2 w/v% C was mixed with 3 mg/ml collagen (Advanced Biomatrix) at a 1:1
volume ratio to produce Col solution. Frozen Films were prepared by cleaning coverslips with 1
M NaOH and 70% ethanol and coated with 20 µl, 50 µl, and 100 µl of C or Col solutions using a
foam brush to produce 20 µm, 60 µm, and 200 m thickness Frozen Films. Coated coverslips were
frozen at -20 °C for 30 min and lyophilized for 30 min. Scaffolds were prepared by casting C or
Col solution into a 24-well plate, refrigerated at 4 °C for 1 h, frozen at -20 °C overnight, lyophilized
for 48 h, and cut to 2 mm disks. Airdried films were prepared by adding 100 µl C or Col solution
into a 24-well plate and air-dried overnight. All samples were neutralized with 1 M NaOH under
vacuum for 45 min, washed with DI water three times, followed by immersing in 70 v/v% ethanol
under vacuum for 10 min for sterilization and washed with sterile D-PBS for three times.

5.2.3 SEM Imaging
Frozen Films, scaffolds and air-dried films were sputter coated with Au on the sample
surface and imaged with SEM (JSM-6480) with 50×and 200×magnifications. Frozen Films were
immersed in liquid nitrogen for 10 s and cut in half for cross section imaging.

5.2.4 Pore Size Measurement
The Frozen Film and scaffold pore size was measured using FIJI. SEM images (n = 6
images per group) with 50×and 200×magnifications for Frozen Films and scaffolds, respectively,
were used. The scale is set based on the scale bar of each magnification. An optimized threshold
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was set to select only pores on each image. The ferret diameters were measured for all pores
selected and average was calculated as pore size.

5.2.5 Thickness Measurement
All samples were broken horizontally in the middle, clamped with a locking clamp on the
sample edge and imaged with a 20 x magnification under optical microscope (Leica, Germany).
The Frozen Film thickness is measured based on the image scale bar. Scotch tape with known
thickness was taped on a coverslip and measured with the same method as a control to verify the
accuracy.

5.2.6 Mechanical Characterization
Sample stiffness was measured in dynamic tension for dry samples (n = 10 per group).
Frozen Films and air-dried films were detached from substrates, cut to 8 mm ×6.8 mm rectangular
shape and measured using DMA (242E, NETZSCH, Germany) with 4 N load cell. The test was
set to be 1 HZ frequency, 20 µm amplitude, and 5 min measurement. The average stiffness was
calculated for stiffness.

5.2.7 Cell Seeding
MSCs, C4-2B and A549 cells were cultured in fully supplemented media at 37 °C and 5%
CO2 in a fully humidified incubator. Fully supplemented media for C4-2B and A549 was RPMI1640 media containing 10% FBS and 1% PS, while for MSCs it was α-MEM media with 16.5%
FBS, 1% PS, and 1% L-glutamine. The cells were detached with trypsin-EDTA, centrifuged at
200 × g for 5 min, and resuspended in fully supplemented media. Frozen Films, air-dry films,
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TCPs and ULA samples were seeded with 50,000 cells in 1mL of fully supplemented media in 24well-size plates. Scaffolds were seeded with 50,000 cells in 75 µl dropwise on the surface and 1
mL of fully supplemented media was added after 1.5 h incubation at 37 °C and 5% CO2 in a fully
humidified incubator. Frozen Films and scaffold cultures were transferred to new 24-well plates
after 48 h to avoid any effects from cells attached to the bottom of the well. Matrigel culture was
performed according to a previously published method [326]. Matrigel was thawed in 4°C
overnight, 50 µl of Matrigel was added to 24 well-size plate and incubate at 37 °C and 5% CO2 for
30 min to form gel. Fresh 250 µl of Matrigel was added to 50,000 cells in a 1.5 mL tube,
resuspended and casted on the top of 50 µl of Matrigel to avoid cells grow on TCPs. Matrigel
cultures were incubated for 30 min and 1 mL of fully supplemented media was added. Samples
were cultured for 10 d and the media was changed every other d.

5.2.8 Cell Seeding Efficiency Measurement
Frozen Film and scaffolds were cell seeded with same method. The cells were detached
with trypsin-EDTA, centrifuged at 200 ×g for 5 min, and resuspended in fully supplemented media.
Frozen Films and scaffold samples were seeded with 50,000 cells in 1mL of fully supplemented
media in 24-well-size plates. All cultures were transferred to new 24-well plates after 24 h and
cells remaining in the initial well (n = 5 samples per group) after transferring were detached using
trypsin-EDTA with the same procedure mentioned above and counted with a hemocytometer to
calculate the cell seeding efficiency.
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5.2.9 Alamar Blue Assay
The cell number at 1, 3, 7, and 10 d was quantified by Alamar Blue assay following the
manufacturer’s protocol. Alamar Blue solution was prepared as 10 v/v% Alamar blue reagent in
fully supplemented media and 1 mL was added to each sample (n = 3), then incubated for 1.5 h at
37 °C and 5% CO2. After incubation, 250 μL Alamar Blue solution was taken from each well in
duplicate and transferred to a black 96-well plate to obtain fluorescence intensity using Cytation 5
cell imaging multi-mode plate reader (BioTek, Winooski, VT) at excitation wavelength of 560 nm
and fluorescence emission read at 595 nm. The intensities were then converted into cell numbers
using a standard curve generated with known cell numbers for each cell line.

5.2.10 Phalloidin Staining
The cultures at 3 and 10 d were fixed with 3.7% formaldehyde for 15 min, washed with
PBS three times and kept in PBS at 4°C for phalloidin staining. The blocking buffer and dilution
buffer for staining were 5% BSA. Samples were permeabilized with 0.1 v/v% Triton-x for 10 min
at room temperature and washed three times with PBS. Blocking buffer was added to the samples
and incubated for 30 min at room temperature. Samples were stained with Alexa Fluor 546phalloidin (1:50) in a dark environment for 30 min, washed with washing buffer (1% BSA) twice
and PBS once. Samples were stained with DAPI for 5 min at room temperature on a shaker,
followed by washing three times with PBS and stored in 4°C. Samples were imaged with Cytation
5 using red fluorescent protein (RFP) filter.
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5.2.11 Real time qRT- PCR
All cultures (n = 3 each group) at 1, 3, 7, and 10 d were washed with D-PBS three times to
remove residual media prior to RNA extraction. TRIzol containing 5 M sodium chloride was added
to the samples and incubate at room temperature for 30 s. Trizol solution was collected in a 1.5
mL tube and mixed with 200 µL of chloroform. The mixture was centrifuged at 12,000 × g for 10
min at 4 C and the top aqueous phase was transferred to a new 1.5 mL tube. The solution was
mixed with equal volume of isopropanol and centrifuged at 12,000 × g for 10 min at 4 C. The
supernatant was removed, and 1 mL of isopropanol was added to repeat the process once more.
After centrifugation, the supernatant was aspirated and 1 mL of 100% ethanol was added, followed
by centrifuging at 12,000 × g for 5 min at 4 C. The supernatant was removed, and RNeasy Mini
Kit was used for further RNA purification following the manufacturer’s protocol. Extracted RNA
was synthesized to cDNA using the Bio-Rad iScript™ cDNA Synthesis Kit following the
manufacturer’s protocol. qRT-PCR assessment was performed using Mx3000 Multiplex
Quantitative PCR System (Stratagene, San Diego, CA) with the following cycle conditions: 95 °C
for 10 min, 40 cycles of 30 s at 94 °C for denaturation, 60 s at 55 °C for annealing, and 30 s at
72 °C in for extension. Data was normalized to the GAPDH internal control and presented as
relative fold change compared with TCP cultures using the ∆∆Ct method.

5.2.12 MSC Differentiation Culture
MSC cultures were started differentiating to adipogenesis and osteogenesis 3 days after cell

seeding. Adipogenic media contained 0.5 M dexamethasone (DEX), 0.5 M 3-isobutyl-1methylxanthine (IBMX), and 50 M indomethacin (IM) in fully supplemented -MEM.
Osteogenic media contained 10 nM DEX, 20 mM β-glycerolphosphate (BGP), and 50 M L94

ascorbic acid (LAA) in fully supplemented -MEM. All cultures were grown for 28 d and
differentiation media was replaced every other day.

5.2.13 Alizarin Red and Oil Red O staining
All differentiation cultures were fixed with 3.7% formaldehyde solution for 15 min and
washed three times with PBS prior to staining. Oil Red O stock solution (0.5 w/v%) was prepared
with isopropyl alcohol. The working solution was prepared by diluting 3 parts of stock solution in
2 parts of PBS, and further filtered through 0.22 μm filter. Alizarin red solution (1 w/v%) was
prepared with DI water, pH was adjusted to a range of 4.1 - 4.3, and further filtered through 0.22
μm filter. Adipogenic samples and osteogenic samples were stained with 1 mL of Oil Red O and
Alizarin red, respectively. All samples (n = 3 per group) were incubated for 20 mins at room
temperature, washed with PBS for three times, and imaged with optical microscope.

5.2.14 C4-2B Docetaxel Drug Response
C4-2B cells (12,000/well) were seeded on 96-well size Frozen Films, scaffolds, C-Air,
ULA, and Matrigel. For TCPs and Col-Air cultures, cells (6,000/well) were seeded after 5 d of
scaffold culture to avoid over-confluency. The cultures were treated with 10 nM DTX at 6 d using
DMSO as vehicle (n = 4 per group). This DTX concentration was determined during preliminary
testing on TCPs culture for cytotoxicity. Fully supplemented media containing DMSO only was
used as control groups (n = 4 per group). Cell number was measured with Alamar Blue assay after
72 h of drug treatment and viability was determined by evaluating sample cell number relative to
vehicle cell number.
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5.2.15 A549 Flow Cytometry
A549 cells were stained with CellTrace™ Violet purchased from Invitrogen (Carlsbad, CA)
before cell seeding based on manufactory’s protocol. Cells on all cultures were washed off at 1, 3,
7, and 10 d for flow cytometry. Frozen Film and scaffold cultures were transferred to a new 24well plate to avoid the cells attached to TCPs. Trypsin (1 mL) was added to all samples, incubated
for 10 min, de-activated with 300 μL of fully supplemented media. The cells were washed off
using 1000 μL pipette, filtered through 70 µm filter and collected in a 15 mL tubes. Cells were
centrifuged at 200 × g for 5 min and washed with DPBS twice for flowcytometry.

5.2.16 Statistical Analysis
All data were presented as the mean ± S) of the mean. Statistical significance was set at p
< 0.05 and tested with ANOVA and t-tests (Microsoft Excel). The biological characterization was
performed on two rounds of cultures with at least n = 3 samples per analysis per culture.

5.4 Results and Discussions
5.4.1 Material Characterization
In this study, Frozen Films were prepared with C or Col at three thicknesses, 20 µm, 60
µm and 200 µm. Frozen Films are a highly porous thin film that consists of 30 µm to 60 µm pore
size and fibrous struts. The pore structure changes with film thickness and takes on a more 3D
porous sponge character when prepared at a greater thickness. The C Frozen Films became more
opaque as the thickness increased (Fig. 25).
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Figure 25 Appearance of C frozen films with 20 µm, 60 µm, and 200 µm thickness.

The pore morphology of C and Col Frozen Films, scaffolds, and air-dried films are shown
in Fig. 26 and Fig. 27 respectively. Frozen Films and scaffolds demonstrated interconnected pore
structures, while air-dried films have a flat 2D surface. The SEM images showed that the pore
sizes are increasing from low thickness to high thickness Frozen Films and scaffolds. The crosssection images of C-60 thickness were shown in Fig. 28, which shows that the interconnected pore
structure is throughout the whole Frozen Film rather than only on the surface.

Figure 26. C Frozen Film, scaffolds and air-dried films pore structure. Pore morphology of Frozen
Films, scaffolds, and air-dried films, low (top) and high (bottom) magnification images.
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Figure 27. Col Frozen Films and scaffolds pore structure. Pore morphology of Frozen Film, low
(top) and high (bottom) magnification images.

Figure 28 Cross-section of 60 µm 2 w/v% C showing pore morphology, low (left) and high (right)
magnification images.

The thickness of Frozen Films increased as more materials were added (Fig. 29a, b), while
the scaffolds had the highested thickness and air-dry film had the lowest thickness. The stiffiness
of all samples were measured with dynamic tensile test by DMA. The Frozen Films, scaffold and
air-dry films stiffnesses were measured with DMA in dry conditions (Fig. 29b, c). The stiffnesses
were 2.22 ± 0.18 MPa, 2.22 ± 0.28 MPa, 2.09 ± 0.14 MPa, 2.23 ± 0.62 MPa, and 17.46 ± 2.93
MPa for 20 µm, 60 µm, and 200 µm C Frozen Films, scaffolds, and air-dry films. The stiffnesses
were 2.69 ± 0.31 MPa, 2.73 ± 0.21 MPa, 2.63 ± 0.32 MPa, 2.22 ± 0.40 MPa, and 15.84 ± 1.08
MPa for 20 µm, 60 µm, and 200 µm Col Frozen Films, scaffolds, and air-dry films. Frozen Films
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and scaffolds made with same compositions had simialr stiffness, since tensile test avoided the
influence of pore structure and only material self were evaluated. The larger pore size on thicker
Frozen Films and scaffolds were verified through pore size measurements (Fig. 29e, f). The pore
size were 22.25 ± 12.6 µm, 35.63 ± 17.79 µm, 50.07 ± 18.83 µm, and 243.09 ± 85.07 µm for 20
µm, 60 µm, and 200 µm C Frozen Films and scaffolds. The pore size were 36.10 ± 13.46 µm,
53.75 ± 11.70 µm, 70.66 ± 20.67 µm, and 280.3 ± 52.3 µm for 20 µm, 60 µm, and 200 µm Col
Frozen Films and scaffolds. Frozen Film and scaffolds made with Col had larger pore size than C
samples, since the Col solution was less viscous than C solution, which allowed larger ice crystial
formation [230, 231].

Figure 29. Frozen Films, scaffolds and air-dry films material properties. a-c) Thickness, stiffness
and pore size for C Frozen Films, scaffolds and air-dry films. d-f) Thickness, stiffness and pore
size for Col Frozen Films, scaffolds and air-dry films.
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5.4.2 MSCs Cell Cultures
MSCs were cultured on Frozen Films, scaffolds, air-dry films, ULA and Matrigel for 10 d and
further differentiated to angiogenesis and osteogenesis for 14 d and 28 d. The MSCs morphology on all
cultures were evaluated through actin staining at 3 and 10 d (Fig. 30). MSCs on all C samples, Col-200,
Col-Scaffolds, ULA, and Matrigel formed spheroids, while elongated cell morphology was found on Col20, Col-60, Col-Air, and TCP cultures. Chitosan is not a ligand for cell binding, which could cause the cell
spheroid formation on all C samples, while the formation of spheroids on Col-200 and Col-scaffolds could
because that the pore size on those samples were larger than Col-20 and Col-60, where it was easier for
cells to aggregate and form spheroids. The cells on scaffolds and Matrigel samples were at different focal
planes (white arrows), which made it harder to focus on cells than Frozen Film cultures, suggesting that
Frozen Film cultures can provide better imaging quality compared with commercial products.

a)

b)

Figure 30. MSCs cellular morphology on all samples at 3 and 10 d. White Arrows indicate out of
focus cells.
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The cell number at 1, 3, 7 and 10 d were measured with Alamar Blue assay (Fig. 31). Col-air and
TCP cultures had the highest cell number throughout all time points, followed by Col-20 and Col-60. This
could be caused by the monolayer cell morphology on those samples, where all cells exposed to the media
directly. A portion of MSCs in C-20 and C-60 cultures and all cells in C-Air and ULA cultures were in
suspended growth with spheroids morphology, where cells were not attached to the matrix. The suspended
cells were easier to be aspirated during media change, led to lower cell number compared with other samples
throughout the culture. The cell number on Col samples decreased from Col-20 to Col-scaffolds, since the
spindle like cell morphology on Col-20 and Col-60 cultures exposed to the media completely, while the
cell on Col-200 and Col-scaffolds had slower oxygen and nutrient diffusion in spheroids.

Figure 31. MSCs cell number at 1, 3, 7 and 10 d.

The stemness for all MSCs cultures were evaluated at 1, 3, 7 and 10 d with qRT-PCR for SOX2,
OCT4 and NANOG markers (Fig. 32, 33). All samples had similar stemness marker expression at 1 d, since
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the cells were only in different culture condition for 24 h. The SOX2, OCT4 and NANOG markers were
upregulated for all samples at 3 d or 7 d compared with TCP culture, suggested that those MSCs had higher
stemness than TCP cells. The MSCs formed spheroids morphology on chitosan samples, Col-200, Colscaffolds and ULA had generally higher SOX2, OCT4 and NANOG markers expression compared with
monolayer culture. Col-Air culture had similar stemness marker expression compared with TCP culture.
a)

b)

Figure 32. MSCs SOX2 (a) and OCT4 (b) marker expression at 1, 3, 7 and 10 d for all cultures.

Figure 33. MSCs NANOG marker expression at 1, 3, 7 and 10 d for all cultures.

All MSCs cultures were cultured for 14 d and 28 d for adipogenesis and osteogenesis differentiation.
The Oil Red O staining for adipogenesis were shown below (Fig. 34). MSCs had positive staining at 14 and
28 d for all cultures, suggested the lipid formation. The adipogenesis differentiation was further evaluated
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with qRT-PCR with LPL, CEBPA and PPARG markers (Fig. 35). All samples had positive expression for
those adipogenic markers. C Frozen Film cultures generally had lower adipogenic marker expression on 14
d compared with TCP but reach to similar level at 28 d. Col Frozen Film cultures generally had similar
adipogenesis marker expression compared with TCP throughout the culture.

a)

b)

Figure 34. MSCs adipogenesis differentiation on all samples at 14 and 28 d. a) C samples and
ULA. (b) Col samples and Matrigel.
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a)

b)

Figure 35. Adipogenesis marker expression for all cultures at a) 14 d and b) 28 d

The Alizarin staining for osteogenesis were shown below (Fig. 36). MSCs had positive staining on
14 and 28 d for all cultures, suggested the formation of mineralization. The osteogenic differentiation was
further evaluated with qRT-PCR with ALPL, COL1A1, and RUNX2 markers (Fig. 37). All Frozen Films
cultures generally had similar osteogenesis marker expression on 14 d compared with TCP but the ALPL
and COL1A1 marker expressions were downregulated at 28 d.
a)

b)

Figure 36. MSCs osteogenic differentiation on all samples at 14 and 28 d.
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a)

b)

Figure 37. Osteogenic marker expression for all cultures at a) 14 d and b) 28 d
5.4.2 C4-2B Cell Cultures
C4-2B cells were cultured on Frozen Films, scaffolds, air-dry films, ULA, Matrigel and TCP for
10 d. The C4-2B cell morphology on all cultures were evaluated through actin staining at 3 and 10 d (Fig.
38). Similar as MSCs, C4-2B cells on all C samples, Col-200, Col-Scaffolds, ULA, and Matrigel formed
spheroids, while elongated cell morphology was found on Col-20, Col-60, Col-Air, and TCP cultures. The
cell spheroids formation on C samples could also due to chitosan is not a cellular ligand, while the formation
of spheroids on Col-200 and Col-scaffolds could be related to Frozen Film pore size.
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a)

b)

Figure 38. C4-2B cellular morphology on all samples at 3 and 10 d. White Arrows indicate out of
focus cells.

The cell number at 1, 3, 7 and 10 d were measured with Alamar Blue assay (Fig. 39). Col-air and
TCP cultures had the highest cell number throughout all time points. This could be caused by the monolayer
cell cultures on those samples, where all cells exposed to the media directly. The cell number on chitosan
samples decrease from C-20 to C-scaffolds due to the increasing of thickness, while all collagen 3D culture
samples had similar cell number throughout the culture. ULA did not well support the C4-2B cell growth,
while Matrigel cultures had similar cell number as collagen samples throughout the culture.
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Figure 39. C4-2B cell number at 1, 3, 7 and 10 d.

The EMT related markers for C4-2B cultures were evaluated at 1, 3, 7 and 10 d with qRT-PCR for
CDH1, TWIST and SNAIL markers (Fig. 40, 41). All cultures generally had lower CDH1 expression than
TCP throughout the culture. However, no specific trends were found related to the compositions or
thickness of samples. TWIST and SNAIL expression was upregulated from 1 to 10 d for most of the samples.
For these two markers, the expression was increased from C-20 to C-200 cultures. Chitosan samples
generally had higher TWIST expression compared with collagen samples, while the SNAIL expression was
generally similar.

107

a)

b)

Figure 40. C4-2B (a) TWIST and (b) SNAIL gene expression at 1, 3, 7 and 10 d for all cultures.

Figure 41. C4-2B CDH1 gene expression at 1, 3, 7 and 10 d for all cultures.

The drug resistance for C4-2B cell culture was evaluated using 10 nM DTX, which was
applied at 6 d and incubated for 72 h. The cell viabilities for all cultures were normalized to the
TCP culture was shown below (Fig. 42). All cultures had higher drug resistance than TCP
culture, including col-air culture. C4-2B drug resistance was promoted in higher thickness
samples, close to Matrigel. Samples with spheroid cell morphology generally had higher drug
resistance, since the drug was harder to diffuse in the cell spheroids.
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Figure 42. Cell viability of C4-2B cells on all cultures after DTX treatment for 72 h. The results
were normalized to the vehicle control for each group.
5.4.3 A549 Cell Cultures
A549 cells were cultured on Frozen Films, scaffolds, air-dry films, ULA, Matrigel and TCP for 10
d. The A549 cell morphology on all cultures were evaluated through actin staining at 3 and 10 d (Fig. 43).
Similar as MSCs and C4-2B, A549 cells on all C samples, Col-200, Col-Scaffolds, ULA, and Matrigel
formed spheroids, while elongated cell morphology was found on Col-20, Col-60, Col-Air, and TCP
cultures.
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a)

b)

Figure 43. A549 cellular morphology on all samples at 3 and 10 d. White Arrows indicate out of
focus cells.

The cell number at 1, 3, 7 and 10 d were measured with Alamar Blue assay (Fig. 44). C-Air, Colair and TCP cultures had the highest cell number throughout all time points. Similar as MSCs and C4-2B,
this could due to the direct exposure to media and oxygen for those monolayer cultures. The cell number
on both chitosan and collagen samples decreased from low to high thickness Frozen Films and scaffolds.
The Frozen Films cultures better supported cell growth compared with ULA, while similar as Matrigel.
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Figure 44. A549 cell number at 1, 3, 7 and 10 d

The EMT related markers for A549 cultures were evaluated at 1, 3, 7 and 10 d with qRT-PCR for
MMP2 and TGF-β (Fig. 45). Most of the samples had highest MMP2 expression on 7 d and decreased on
10 d, and TGF-β expression reached highest at 3 d and decreased after 3 d. Compared with TCP, most of
the samples had upregulated MMP2 expression, while the TGF-β expression was down-regulated.
a)

a)

Figure 45. A549 (a) MMP2 and (b) TGF-β gene expression at 1, 3, 7 and 10 d for all cultures.
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The hypoxia related markers for A549 cultures were evaluated at 1, 3, 7 and 10 d with
qRT-PCR for HIF1-α markers (Fig. 46). Compared with TCP culture, most of the samples had upregulated expression at various time points. The NK cell treatment was partly done, need to be
finalized later.

Figure 46. A549 HIF1-α gene expression at 1, 3, 7 and 10 d for all cultures.

The immutherapy related markers for A549 cultures were evaluated at 1, 3, 7 and 10 d with
qRT-PCR for HLA-E and PD-L1 markers (Fig. 47). For most of the samples, HLA-E and PD-L1
expression decreased from 1 d to 10 d. Compared with TCP, HLA-E and PDL1 was downregulated for most of the samples. The NK cell treatment was partly done, need to be finalized
later
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a)

B)

Figure 47. A549 (a) HLA-E and (b) PD-L1 gene expression at 1, 3, 7 and 10 d for all cultures.
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CHAPTER 6: SUMMARY
During my PhD program, I investigated the interaction between PCa cells and ECM through
adjusting CA scaffold stiffness and CS concentration in C-CS scaffold. 2, 4 and 6 w/v% CA
scaffolds, with increasing stiffness were used to mimic three stages of PCa progression. CA
scaffolds were found to have the ability to discern the phenotypic differences of osteolytic and
osteoblastic PCa cells, while the cell growth and phenotypic marker expression was independent
of CA scaffold stiffness. This could be due to alginate being bioinert. Therefore, I replaced alginate
in the scaffolds with CS, since CS was found in normal prostate tissue, greater in PCa, and further
in metastatic PCa. C-CS scaffolds with three compositions, 4-0.1, 4-0.5 and 4-1, were produced
and used to culture PC cells. All C-CS scaffolds promoted PCa cell EMT compared with 2D
culture and EMT maker expression was upregulated with increasing CS concentration. PCa cells
also demonstrated higher drug resistance on C-CS scaffold compared with 2D culture and 4-1
scaffold culture had the highest drug resistance among all samples. The results of these two
projects did provide more insights in PCa, however, I also realized that 3D cell culture had many
challenges on operation compare with 2D culture, which strongly limited its application in industry.
Therefore, I developed a new cell culture substrate, named Frozen Films, which supports 3D cell
culture, but is as easy to use as 2D. The results showed that cells on Frozen Film cultures had
similar drug resistance and immunotherapy resistance as commercialized 3D culture models, ULA
and Matrigel cultures. Frozen Films could also better support cell proliferation compared with
ULA cultures and was easier to operate compared with Matrigel. These suggested that Frozen
Films has potential applications for in vitro anti-cancer drug screening and immunotherapy
development.
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